{"gene":"CMKLR1","run_date":"2026-06-09T22:57:18","timeline":{"discoveries":[{"year":1996,"finding":"CMKLR1 (chemokine-like receptor 1) was cloned as a novel human gene encoding a seven-transmembrane G protein-linked receptor with 55% nucleotide homology to the IL-8 type 1 receptor and 53% to the N-formyl peptide related receptor 1, and was localized to human chromosome 12q24.1 by fluorescence in situ hybridization. mRNA is expressed in hematopoietic and immune tissues.","method":"Molecular cloning, FISH chromosomal mapping, Northern blot/expression analysis","journal":"Cytogenetics and cell genetics","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct cloning and chromosomal localization by FISH, foundational study","pmids":["8976386"],"is_preprint":false},{"year":1998,"finding":"CMKLR1 (ChemR23) is expressed abundantly in monocyte-derived dendritic cells and macrophages and functions as a coreceptor for SIV strains (SIVmac316, SIVmac239, SIVmac17E-Fr, SIVsm62A) and a primary HIV-1 strain (92UG024-2) in cell fusion assays, but not for tested HIV-2 strains.","method":"RT-PCR expression analysis, cell fusion coreceptor assay","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct functional fusion assay with multiple viral strains, foundational characterization paper","pmids":["9603476"],"is_preprint":false},{"year":2003,"finding":"TIG2 (chemerin, encoded by RARRES2) was identified as the natural ligand of CMKLR1 (ChemR23) through reverse pharmacology screening of a peptide library from human hemofiltrate; the active circulating form corresponds to amino acid residues 21–154 of the 163 aa prepropeptide.","method":"Reverse pharmacology peptide library screening, biochemical characterization","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct ligand identification by reverse pharmacology, endogenous peptide isolated and characterized","pmids":["14675762"],"is_preprint":false},{"year":2005,"finding":"CMKLR1 (ChemR23) is expressed and functional on blood plasmacytoid and myeloid dendritic cells; recombinant chemerin induces transmigration of these cells across an endothelial cell monolayer. ChemR23 is expressed on the luminal side of high endothelial venules in secondary lymphoid organs, directing DC trafficking.","method":"Flow cytometry, transendothelial migration assay, immunohistochemistry","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional transmigration assay with primary cells plus in situ localization data, replicated across multiple tissue types","pmids":["15728234"],"is_preprint":false},{"year":2007,"finding":"RvE1 binds directly to CMKLR1 (ChemR23) on human PBMC and induces calcium mobilization; it also acts as a partial agonist at BLT1. At higher doses, RvE1's anti-inflammatory actions in vivo are BLT1-independent, consistent with ChemR23-mediated effects.","method":"[3H]RvE1 radioligand binding assay (membrane fractions), calcium mobilization assay, in vivo peritonitis model with BLT1 KO mice","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct radioligand binding with Kd determination, multiple orthogonal functional assays, genetic KO model","pmids":["17339491"],"is_preprint":false},{"year":2008,"finding":"Proteolytically processed murine chemerin and derived C-terminal peptide chemerin15 (C15, residues A140–A154) exert anti-inflammatory effects entirely dependent on ChemR23; C15 suppressed neutrophil and monocyte recruitment in zymosan-induced peritonitis in wild-type but not ChemR23-/- mice, demonstrating absolute ChemR23 dependence.","method":"In vitro macrophage activation assay, in vivo peritonitis model using ChemR23 knockout mice, neutralizing antibody experiments","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout confirmation, multiple orthogonal in vivo and in vitro assays, replicated in two labs","pmids":["18391062"],"is_preprint":false},{"year":2009,"finding":"Mouse CMKLR1 (ChemR23) is highly expressed on immature plasmacytoid DCs and at lower levels on myeloid DCs, macrophages, and NK cells. Chemerin promotes calcium mobilization and chemotaxis on these cells, and these responses are abrogated in ChemR23 knockout mice. Mouse prochemerin requires C-terminal processing to generate an active ChemR23 agonist.","method":"Flow cytometry, calcium mobilization assay, chemotaxis assay, ChemR23 KO mice, structural/pharmacological analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — functional assays with primary cells confirmed by genetic KO, multiple cell types and assays","pmids":["19841182"],"is_preprint":false},{"year":2009,"finding":"CMKLR1 (ChemR23) is expressed in human endothelial cells and is upregulated by pro-inflammatory cytokines TNF-α, IL-1β, and IL-6. Chemerin acting via ChemR23 induces endothelial angiogenesis, MMP-2 and MMP-9 gelatinolytic activity, and dose-dependently activates PI3K/Akt and MAPK signaling pathways.","method":"In vitro angiogenesis assays, gelatin zymography, Western blot for PI3K/Akt and MAPK phosphorylation","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple functional assays in a single lab, no genetic KO confirmation","pmids":["20044979"],"is_preprint":false},{"year":2010,"finding":"Knockdown of CMKLR1 by RNA interference abrogated adipocyte differentiation, clonal expansion, and basal proliferation of bone marrow stromal cells (BMSCs), and was associated with increased osteoblast marker gene expression and mineralization. Forced PPARγ expression induced chemerin and partially rescued loss of adipogenesis caused by CMKLR1 knockdown, placing CMKLR1 downstream of PPARγ in a chemerin autocrine loop.","method":"siRNA knockdown, adipogenesis/osteoblastogenesis differentiation assays, PPARγ overexpression rescue, primary BMSC cultures","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — siRNA knockdown with multiple orthogonal differentiation readouts and genetic rescue experiment in primary cells","pmids":["19929432"],"is_preprint":false},{"year":2010,"finding":"CMKLR1 (ChemR23) promotes phagocytosis of microbial particles and efferocytosis of apoptotic cells in macrophages by a mechanism involving increased actin polymerization and F-actin localization to the phagocytic cup in a Syk kinase-dependent manner; these prophagocytic effects are absent in ChemR23-/- macrophages and completely abrogated by pharmacological Syk inhibition.","method":"Phagocytosis/efferocytosis assays, ChemR23 KO macrophages, pharmacological Syk inhibition, F-actin imaging, in vivo peritoneal clearance assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO and pharmacological inhibition combined, multiple orthogonal assays, in vitro and in vivo confirmation","pmids":["20363975"],"is_preprint":false},{"year":2010,"finding":"Chemerin stimulation of human articular chondrocytes via ChemR23 activates ERK1/2 (p44/p42 MAPK) and Akt (Ser473) phosphorylation and significantly increases secretion of pro-inflammatory cytokines (IL-6, IL-8, TNF-α, IL-1β) and matrix metalloproteases (MMP-1, MMP-2, MMP-3, MMP-8, MMP-13).","method":"Western blot for phospho-MAPK and phospho-Akt, cytokine ELISA, MMP measurement in cell supernatants, primary chondrocyte cultures","journal":"Arthritis research & therapy","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple signaling and functional readouts, single lab, no genetic KO confirmation","pmids":["21192818"],"is_preprint":false},{"year":2011,"finding":"ChemR23 deficiency in mice leads to reduced plasmacytoid DC recruitment to lungs during viral pneumonia, decreased type I interferon production, and increased neutrophilic infiltration, demonstrating a dual role: ChemR23-dependent pDC recruitment contributes to viral clearance but also promotes inflammation, while a separate ChemR23-dependent anti-inflammatory pathway in non-leukocytic cells reduces morbidity/mortality.","method":"ChemR23 KO mice, PVM infection model, pDC depletion, adoptive transfer, chimeric mice","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models including KO, depletion, adoptive transfer, and chimeras; multiple orthogonal readouts","pmids":["22072972"],"is_preprint":false},{"year":2011,"finding":"CMKLR1 (ChemR23) deficiency in mice results in reduced adiposity (lower body mass and percent body fat), decreased hepatic dendritic cell infiltration, decreased adipose CD3+ T cells, increased adipose NK cells, and impaired glucose-stimulated insulin secretion and glucose uptake in skeletal muscle and white adipose tissue, establishing CMKLR1 as a regulator of adipose development, inflammation, and glucose homeostasis in vivo.","method":"CMKLR1 KO mouse model, body composition analysis, glucose tolerance/insulin secretion tests, flow cytometry of immune infiltrates, tissue glucose uptake assay","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — comprehensive KO phenotyping with multiple orthogonal metabolic and immunological readouts","pmids":["22186410"],"is_preprint":false},{"year":2013,"finding":"ChemR23 forms homomers and heteromers with chemokine receptors CCR7 and CXCR4 as demonstrated by BRET and HTRF assays. Negative binding cooperativity was detected between ChemR23 and these chemokine receptors: ligands of one receptor competed for binding of a tracer to the other. In primary mouse bone marrow-derived DCs from wild-type vs ChemR23 KO mice, ChemR23-specific ligands cross-inhibited CXCL12 binding on CXCR4 in a ChemR23-dependent manner.","method":"BRET assay, HTRF assay, radioligand binding competition, ChemR23 KO bone marrow-derived DCs","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — BRET and HTRF for heteromerization, validated with genetic KO primary cells, single lab","pmids":["23469143"],"is_preprint":false},{"year":2013,"finding":"ChemR23 is expressed in neutrophil granules and is rapidly upregulated upon neutrophil activation. The C15/ChemR23 pathway inhibits integrin activation and clustering, reduces neutrophil adhesion and chemotaxis in vitro, and induces adherent cell detachment from inflamed endothelium in vivo, reducing neutrophil recruitment and heart damage in a murine myocardial infarction model through ChemR23.","method":"Flow cytometry, immunofluorescence (granule localization), integrin activation assays, intravital microscopy, murine MI model, ChemR23-dependent pharmacological experiments","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — subcellular localization established, multiple functional assays in vitro and in vivo with ChemR23-dependent mechanism confirmed","pmids":["23999103"],"is_preprint":false},{"year":2014,"finding":"CMKLR1 small molecule antagonist α-NETA inhibits chemerin-stimulated β-arrestin2 association with CMKLR1 and chemerin-triggered CMKLR1+ cell migration, and significantly delayed EAE onset and reduced CNS mononuclear cell infiltrates when administered to mice, pharmacologically recapitulating the CMKLR1 KO phenotype.","method":"β-arrestin2 recruitment assay, cell migration assay, EAE model (active immunization and adoptive transfer), CNS histology","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — mechanistic assays for β-arrestin recruitment and migration plus in vivo EAE model, single lab","pmids":["25437209"],"is_preprint":false},{"year":2015,"finding":"Chemerin binds to CMKLR1 (and GPR1 and CCRL2) with low nanomolar affinity. Binding of chemerin and the chemerin-9 nonapeptide (149YFPGQFAFS157) to CMKLR1 activates Gαi1, Gαi2, Gαi3, Gαoa, and Gαob (but not Gαs or Gαq), and recruits β-arrestin1 and β-arrestin2. ERK1/2 phosphorylation requires both Gαi/o and β-arrestin2 but not β-arrestin1. GPR1 does not activate G proteins but does recruit β-arrestins. CCRL2 does not activate G proteins or recruit β-arrestins.","method":"BRET-based biosensors for G protein activation and β-arrestin recruitment, radioligand binding, ERK phosphorylation with pathway-specific inhibitors","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — BRET biosensors for multiple G protein subtypes, multiple orthogonal methods including binding and downstream signaling, comprehensive pharmacological dissection","pmids":["27716822"],"is_preprint":false},{"year":2015,"finding":"CMKLR1 is a functional receptor for amyloid-β peptide (Aβ42): Aβ42 binds specifically to CMKLR1 in stably transfected RBL cells, induces CMKLR1-dependent cell migration via ERK1/2, PKA, and Akt pathways (but not Ca2+ mobilization), and stimulates internalization of the Aβ42-CMKLR1 complex in microglia and CMKLR1-RBL cells.","method":"Radioligand-equivalent binding in stably transfected RBL cells, migration assays (N9 microglia, primary microglia, CMKLR1-RBL vs untransfected RBL), pathway inhibitor studies, internalization assay","journal":"Journal of Alzheimer's disease","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — specific binding and migration shown with CMKLR1-expressing vs non-expressing cells, multiple pathway readouts, single lab","pmids":["25079809"],"is_preprint":false},{"year":2015,"finding":"CMKLR1 signals through a RhoA/ROCK-dependent pathway to activate the transcriptional regulator SRF; chemerin-mediated chemotaxis requires p38, Gαi/o, RhoA, and ROCK signaling. Species-specific and receptor-dependent differences in GPR1 and CMKLR1 signaling were demonstrated.","method":"Luciferase reporter assays (SRF, CRE, NF-κB), pathway-specific inhibitors, chemotaxis assay in L1.2 and AGS cells","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple reporter assays and pharmacological inhibition, single lab, no genetic KO confirmation","pmids":["26363224"],"is_preprint":false},{"year":2015,"finding":"ChemR23 is differentially expressed in macrophage polarization states: LPS or IFN-γ stimulation increases transcription from promoter P3 in M1 macrophages. M1 macrophages expressing ChemR23 are chemotactic to chemerin, while M2 macrophages without surface ChemR23 are not. RvE1 (10 nM) acting through ChemR23 on M1 macrophages increases IL-10 transcription and phagocytosis of microbial particles, driving resolution-type repolarization.","method":"5' RACE (promoter identification), flow cytometry, qPCR, chemotaxis assay, phagocytosis assay, primary human macrophages","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — 5' RACE for promoter characterization, multiple functional assays (chemotaxis, phagocytosis, cytokine measurement) in primary human cells, mechanistic promoter analysis","pmids":["25637017"],"is_preprint":false},{"year":2016,"finding":"Chemerin exerts vasoconstrictor actions via CMKLR1 but not GPR1 in human and rat vasculature: the chemerin C-terminal peptide C9 (chemerin149-157) contracted human saphenous vein and resistance arteries and increased blood pressure in rats, and these effects were blocked by the selective CMKLR1 antagonist CCX832. C9 inhibited cAMP accumulation in human aortic smooth muscle cells and showed ~5000-fold bias toward Gi protein signaling over other pathways (biased agonism at CMKLR1).","method":"Isometric tension (vascular contraction), blood pressure measurement in rats, cAMP accumulation assay, selective antagonist CCX832, immunohistochemistry for receptor localization","journal":"Journal of the American Heart Association","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct functional pharmacology with selective antagonist, multiple vascular preparations, in vivo confirmation, receptor localization","pmids":["27742615"],"is_preprint":false},{"year":2016,"finding":"Nanobodies (CA4910 and CA5183) targeting the native conformation of ChemR23 bind to a site overlapping with the chemerin binding site and act as antagonists of chemerin-induced intracellular calcium increase and chemotaxis of human primary cells. A bivalent CA4910 nanobody showed enhanced antagonist efficacy. The chemerin C-terminal nonapeptide (chemerin149-157) binding site on ChemR23 largely overlaps with the chemerin binding site.","method":"Phage display/genetic immunization (nanobody development), competition binding assays, calcium mobilization assay, chemotaxis assay, flow cytometry with primary cells","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — competition binding defines overlapping binding sites, multiple functional assays in transfected and primary cells, bivalent construct validates specificity","pmids":["26864035"],"is_preprint":false},{"year":2018,"finding":"Targeted deletion of the resolvin E1 receptor Erv1/ChemR23 in hyperlipidemic mice (Apoe-/-) leads to proatherogenic macrophage signaling, increased oxidized LDL uptake, reduced phagocytosis, and increased atherosclerotic plaque size and necrotic core formation. RvE1-mediated effects on oxLDL uptake and phagocytosis in macrophages are dependent on Erv1/ChemR23.","method":"ChemR23/Apoe double KO mice, histological plaque analysis, macrophage phagocytosis assay, oxLDL uptake assay, lipidomic plasma analysis","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO model with multiple functional macrophage assays and in vivo atherosclerosis outcome, independent validation in two hyperlipidemic mouse models","pmids":["29739755"],"is_preprint":false},{"year":2018,"finding":"Chemerin-activated CMKLR1 signaling in inflammatory macrophages is regulated by GRK6-mediated phosphorylation and β-arrestin 2 recruitment: co-expression of GRK6 enhances β-arrestin recruitment to CMKLR1 after chemerin stimulation; GRK6- and β-arrestin 2-deficient macrophages show decreased CMKLR1 internalization, increased migration toward chemerin, and altered AKT and ERK signaling.","method":"BRET/co-IP β-arrestin recruitment assay, flow cytometry internalization assay, GRK6 KO and β-arrestin 2 KO primary macrophages, migration assay, Western blot (AKT, ERK)","journal":"Molecular immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO macrophages combined with overexpression and multiple signaling readouts, mechanistic dissection of GRK/arrestin regulation","pmids":["30576947"],"is_preprint":false},{"year":2018,"finding":"Chemerin suppresses HCC metastasis through a CMKLR1-PTEN-Akt signaling axis: chemerin interferes with the PTEN-CMKLR1 protein interaction (shown by immunoprecipitation), upregulates PTEN expression and phosphatase activity, reduces PTEN ubiquitination, and decreases p-Akt (Ser473), thereby suppressing HCC cell migration and invasion.","method":"Co-immunoprecipitation, forced expression/RNAi, PTEN phosphatase activity assay, ubiquitination assay, Western blot, in vivo mouse metastasis models","journal":"British journal of cancer","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — co-IP demonstrates PTEN-CMKLR1 interaction, multiple orthogonal assays (phosphatase activity, ubiquitination, in vivo), single lab","pmids":["29717200"],"is_preprint":false},{"year":2018,"finding":"Chemerin acting via ChemR23 in keratinocytes triggers inflammatory responses through a ROS-sirt1-NF-κB signaling pathway: chemerin increases ROS production, suppresses sirt1 expression and deacetylase activity, leading to increased NF-κB p65 acetylation and activation, and enhanced secretion of inflammatory cytokines.","method":"ELISA (cytokines), Western blot (NF-κB, sirt1), ROS measurement, in vivo imiquimod mouse psoriasis model","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — multiple signaling readouts with receptor-dependent mechanism, in vivo model, single lab","pmids":["30426542"],"is_preprint":false},{"year":2019,"finding":"CMKLR1 in vascular smooth muscle cells (VSMCs) acts as a determinant of synthetic and osteoblastic phenotype, promoting phosphate-induced calcification: ChemR23-deficient VSMCs maintain a non-synthetic phenotype and resist phosphate-induced calcification; ChemR23-deficient mice are protected against vitamin D3-induced vascular calcification. Resolvin E1 inhibits VSMC calcification through ChemR23.","method":"ChemR23 KO mice, primary VSMC isolation, calcification assays, phenotype marker gene expression, in vivo vitamin D3 calcification model, Fat-1 transgene experiments","journal":"Cardiovascular research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO primary cells and in vivo model, multiple orthogonal functional assays, ChemR23-dependent rescue with RvE1","pmids":["30597013"],"is_preprint":false},{"year":2019,"finding":"Chemerin recruits NK cells to the tumor microenvironment via CMKLR1: CMKLR1-/- and chemerin-/- (Rarres2-/-) mice showed impaired tumor-infiltrating NK cells in murine melanoma models, and the NK cell-enhancing and tumor-inhibitory effects of all-trans retinoic acid were completely abrogated in both Rarres2-/- and Cmklr1-/- mice, demonstrating a required chemerin-CMKLR1 axis for NK cell recruitment.","method":"Chemerin KO and CMKLR1 KO mouse tumor models, flow cytometry of tumor-infiltrating NK cells, atRA treatment","journal":"Immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent genetic KO models (ligand and receptor) both ablate the same phenotype, in vivo tumor model","pmids":["31063220"],"is_preprint":false},{"year":2019,"finding":"Chemerin inhibits vascular calcification through ChemR23 in VSMCs: chemerin reduces phosphate-induced calcification and increases matrix gla protein (MGP) expression in wild-type VSMCs but is devoid of these effects in VSMCs lacking ChemR23.","method":"Primary VSMC calcification assay, ChemR23 KO VSMCs, MGP expression measurement","journal":"Journal of internal medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO cells confirm receptor dependence, single lab, limited mechanistic depth","pmids":["31197872"],"is_preprint":false},{"year":2019,"finding":"ChemR23 (CMKLR1) deficiency in hematopoietic cells reduces atherosclerosis by promoting M2 macrophage polarization, increasing cholesterol efflux, and reducing pDC frequency and their migration to atherosclerotic lesions. ChemR23-deficient pDCs show reduced migratory capacity and decreased CCR7 expression; adoptive transfer confirmed reduced accumulation of ChemR23-KO pDCs in lesions.","method":"ChemR23 KO/knockin eGFP reporter mice crossed to Apoe-/- mice, bone marrow transplantation (hematopoietic KO), pDC adoptive transfer, histology, flow cytometry, gene expression","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — hematopoietic-specific KO and adoptive transfer experiments establish cell-autonomous function, multiple orthogonal readouts","pmids":["30786742"],"is_preprint":false},{"year":2020,"finding":"The chemerin/CMKLR1 axis promotes inflammation and pyroptosis in diabetic cardiomyopathy through NLRP3 inflammasome activation: CMKLR1 siRNA attenuated NLRP3 expression, caspase-1 activation, IL-1β maturation, and pyroptosis in vivo. In vitro, silencing either CMKLR1 or NLRP3 suppressed activated caspase-1, IL-1β, and pyroptosis, and combined silencing further decreased IL-1β and pyroptosis, indicating NLRP3 acts downstream of CMKLR1.","method":"siRNA knockdown (CMKLR1, NLRP3) in vivo and in vitro, Western blot, LDH/EthD-III cell death assays, cardiac function measurement","journal":"Frontiers in physiology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — epistasis established by double KD, multiple readouts, single lab","pmids":["32390873"],"is_preprint":false},{"year":2020,"finding":"Chemerin upregulates PTEN expression/activity and suppresses PD-L1 expression in prostate and sarcoma tumor cells via a CMKLR1/PTEN/PD-L1 signaling cascade: CMKLR1 knockdown abrogated both chemerin-induced PTEN upregulation and PD-L1 suppression; PI3K/AKT/mTOR pathway inhibitors mimicked these effects, and forced chemerin expression in DU145 xenografts increased PTEN and decreased PD-L1 in vivo.","method":"siRNA knockdown of CMKLR1, Western blot, specific pathway inhibitors, in vivo xenograft model with forced chemerin expression","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — receptor knockdown plus in vivo confirmation, multiple tumor types, single lab","pmids":["32605911"],"is_preprint":false},{"year":2020,"finding":"n-3 PUFA-derived resolvin E1 and its receptor ChemR23 constitute a key axis restricting aortic valve stenosis progression: abrogation of ChemR23 enhanced disease progression, and the beneficial effects of endogenous n-3 PUFA synthesis (Fat-1 transgene) were abolished in the absence of ChemR23, establishing a required role for ChemR23 in RvE1-mediated inhibition of valvular calcification.","method":"ChemR23 KO mice, Fat-1tg × Apoe-/- mice, echocardiography, histology, lipidomics (LC-MS/MS)","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO epistasis with two independent mouse models, functional echocardiographic and histological outcomes, lipidomic validation","pmids":["32506925"],"is_preprint":false},{"year":2021,"finding":"An agonist anti-ChemR23 monoclonal antibody induces ChemR23 receptor signaling, promotes macrophage efferocytosis, and reduces neutrophil tissue accumulation. In ongoing chronic colitis models, the antibody triggered resolution with decreased tissue lesions, fibrosis, and inflammation-driven tumors, demonstrating that GPCR agonism at ChemR23 is sufficient to drive resolution of chronic inflammation.","method":"Agonist mAb characterization, efferocytosis assay, neutrophil apoptosis assay, chronic colitis mouse models, transcriptional analysis in IBD patients","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — novel agonist antibody with mechanistic in vitro validation (efferocytosis, receptor signaling) and in vivo disease model, multiple endpoints","pmids":["33811066"],"is_preprint":false},{"year":2021,"finding":"The chemerin-CMKLR1 axis restricts cold-induced thermogenesis and beige fat formation by dampening cAMP-PKA signaling in adipocytes, thereby reducing IL-33 production from beige adipocytes and interrupting a feed-forward circuit between beige adipocytes and type 2 innate immunity. Adipocyte-specific CMKLR1 deletion enhanced beige fat and thermogenesis and protected against diet-induced obesity.","method":"Adipocyte-specific CMKLR1 knockout mice, cold exposure experiments, cAMP/PKA signaling assays, IL-33 measurement, type 2 innate immune cell analysis, metabolic phenotyping","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional cell-type-specific KO identifies adipocyte-autonomous mechanism, cAMP-PKA signaling dissected, multiple orthogonal readouts","pmids":["34330814"],"is_preprint":false},{"year":2022,"finding":"The chemerin-CMKLR1 axis in intestinal epithelial cells (IECs) restricts microbiota-driven colonic neutrophilia and tumorigenesis by upregulating lactoperoxidase (LPO): IEC-specific CMKLR1 deletion reduced LPO expression, causing outgrowth of gram-negative bacteria and dysregulated CXCL1/2-mediated neutrophilia; LPO supplementation fully rescued these phenotypes.","method":"Intestinal epithelial cell-specific CMKLR1 KO mice, LPO expression analysis, microbiome analysis, neutrophil quantification, LPO supplementation rescue experiment","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with genetic rescue (LPO supplementation), mechanistic pathway identification, multiple orthogonal readouts","pmids":["35858331"],"is_preprint":false},{"year":2022,"finding":"Chemerin enhances mesenchymal features of glioblastoma cells through a CMKLR1-dependent mechanism: chemerin suppresses ubiquitin-proteasomal degradation of CMKLR1, thereby enhancing NF-κB pathway activation; this CMKLR1/NF-κB axis also drives M2 polarization of tumor-associated macrophages and their mesenchymal phenotype-promoting ability. α-NETA blockade disrupted this network.","method":"Co-immunoprecipitation, ubiquitination assay, NF-κB reporter, CMKLR1 overexpression/knockdown, GBM xenograft models, macrophage polarization assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — ubiquitination and co-IP establish mechanism, multiple cell models and in vivo xenograft, single lab","pmids":["35459783"],"is_preprint":false},{"year":2023,"finding":"RvE1/ChemR23 ameliorates hypertension and vascular remodeling by activating AMPKα/Nrf2 signaling: RvE1 inhibited Ccl5 expression in VSMCs via AMPKα/Nrf2/canonical NF-κB pathway (reducing immune cell infiltration) and regulated VSMC phenotypic transformation and proliferation. All effects were reversed by ChemR23 knockdown (AAV9-shRNA).","method":"AAV9-mediated ChemR23 knockdown, Ang II hypertension mouse model, Western blot (AMPKα, Nrf2, NF-κB), blood pressure measurement, histology, qPCR","journal":"Hypertension","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — receptor knockdown confirms ChemR23 dependence, signaling pathway dissected, single lab","pmids":["37800344"],"is_preprint":false},{"year":2024,"finding":"CMKLR1 controls lipid metabolism in clear cell renal cell carcinoma (ccRCC): genetic or pharmacological suppression of CMKLR1 reduced lipid formation and induced apoptosis, ferroptosis, and autophagy. Mechanistically, CMKLR1 suppresses adipose triglyceride lipase (ATGL) and uniquely controls lipid uptake through regulation of sterol regulatory element-binding protein 1c (SREBP1c) and the CD36 scavenger receptor; α-NETA treatment dramatically reduced tumor growth and lipid storage in patient-derived xenograft models.","method":"Genetic knockdown/knockout and pharmacological inhibition (α-NETA), lipidomic and transcriptomic profiling, patient-derived xenograft models, Western blot for ATGL/SREBP1c/CD36","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — comprehensive lipidomics + transcriptomics + in vivo PDX models + mechanistic molecular targets identified, single lab but multiple orthogonal methods","pmids":["38640229"],"is_preprint":false}],"current_model":"CMKLR1 (ChemR23) is a seven-transmembrane Gi/o-coupled GPCR that binds chemerin (TIG2/RARRES2) and resolvin E1 as principal ligands, and also functions as a receptor for amyloid-β42; ligand binding activates Gαi1/2/3 and Gαo isoforms, recruits β-arrestin1/2 (regulated by GRK6-mediated phosphorylation), triggers RhoA/ROCK/SRF, MAPK/ERK, PI3K/Akt, and AMPKα/Nrf2 downstream signaling cascades, forms homomers and heteromers with CXCR4 and CCR7 with negative binding cooperativity, and controls diverse cellular processes including dendritic cell and NK cell chemotaxis, neutrophil granule exocytosis and adhesion, macrophage phagocytosis/efferocytosis and polarization, adipogenesis/thermogenesis, vascular smooth muscle calcification and contraction, and lipid metabolism in cancer cells—with these functions established through genetic knockout models, direct binding assays, and pharmacological dissection across multiple tissues."},"narrative":{"mechanistic_narrative":"CMKLR1 (ChemR23) is a seven-transmembrane G protein-coupled receptor, cloned from human chromosome 12q24.1 and expressed in hematopoietic and immune tissues, that orchestrates leukocyte trafficking, inflammation resolution, and tissue metabolism [PMID:8976386, PMID:14675762]. Its principal endogenous ligand is chemerin (TIG2/RARRES2), identified by reverse pharmacology, whose active forms require C-terminal proteolytic processing to generate ChemR23 agonists [PMID:14675762, PMID:19841182]; the receptor also binds the proresolving lipid mediator resolvin E1 and the amyloid-β42 peptide [PMID:17339491, PMID:25079809]. Chemerin engagement of CMKLR1 activates Gαi/o isoforms (not Gαs or Gαq) and recruits β-arrestin1/2, with ERK1/2 phosphorylation requiring both Gαi/o and β-arrestin2; receptor desensitization and internalization are controlled by GRK6-mediated phosphorylation [PMID:27716822, PMID:30576947]. Downstream the receptor drives RhoA/ROCK/SRF, PI3K/Akt, and MAPK cascades to direct chemotaxis [PMID:20044979, PMID:26363224], and it can signal in a strongly Gi-biased manner to mediate vasoconstriction [PMID:27742615]. Through these pathways CMKLR1 controls dendritic-cell, NK-cell, and macrophage recruitment and function, including macrophage phagocytosis/efferocytosis via a Syk-dependent actin-remodeling mechanism and M1/M2 polarization [PMID:15728234, PMID:20363975, PMID:25637017, PMID:31063220]. The chemerin/RvE1-CMKLR1 axis is a major node in inflammation resolution and cardiometabolic biology: it limits neutrophil recruitment and adhesion in myocardial infarction, restrains atherosclerosis and vascular/valvular calcification, regulates adipogenesis, glucose homeostasis, and cold-induced thermogenesis, and modulates tumor immunity and cancer-cell lipid metabolism [PMID:18391062, PMID:22186410, PMID:29739755, PMID:30597013, PMID:34330814, PMID:38640229]. CMKLR1 additionally forms homomers and heteromers with CXCR4 and CCR7 with negative binding cooperativity [PMID:23469143].","teleology":[{"year":1996,"claim":"Established the molecular identity of CMKLR1 as a candidate chemoattractant GPCR, defining the gene and its genomic location before any ligand was known.","evidence":"Molecular cloning, FISH chromosomal mapping, and Northern expression analysis of the human gene","pmids":["8976386"],"confidence":"High","gaps":["No ligand identified","Signaling mechanism unknown","Function inferred only from homology to chemokine/formyl-peptide receptors"]},{"year":1998,"claim":"Showed the orphan receptor was expressed on dendritic cells and macrophages and could serve as a viral fusion coreceptor, linking it to immune cells before its physiological ligand was defined.","evidence":"RT-PCR expression analysis and cell fusion coreceptor assays with SIV and HIV-1 strains","pmids":["9603476"],"confidence":"High","gaps":["Endogenous ligand still unknown","Physiological role of coreceptor activity unclear","No signaling characterization"]},{"year":2003,"claim":"Deorphanized the receptor by identifying chemerin (TIG2/RARRES2) as its natural ligand, converting CMKLR1 into a defined signaling system.","evidence":"Reverse pharmacology screening of a human hemofiltrate peptide library with biochemical characterization of the active 21–154 form","pmids":["14675762"],"confidence":"High","gaps":["G protein coupling not yet defined","Downstream effectors unknown","Processing requirements for activity not yet resolved"]},{"year":2005,"claim":"Demonstrated that chemerin-CMKLR1 directs functional trafficking of plasmacytoid and myeloid dendritic cells, establishing a bona fide chemoattractant role in immune cell positioning.","evidence":"Flow cytometry, transendothelial migration assays with primary DCs, and immunohistochemistry of high endothelial venules","pmids":["15728234"],"confidence":"High","gaps":["Signaling cascade driving migration not dissected","In vivo trafficking not yet confirmed genetically"]},{"year":2007,"claim":"Identified resolvin E1 as a second direct ligand acting through CMKLR1, connecting the receptor to active resolution of inflammation distinct from its chemerin function.","evidence":"[3H]RvE1 radioligand binding on human PBMC membranes, calcium mobilization, and in vivo peritonitis with BLT1 KO mice","pmids":["17339491"],"confidence":"High","gaps":["Tissue-specific RvE1 effects not separated from BLT1","Downstream resolution mechanism not yet defined"]},{"year":2008,"claim":"Proved that chemerin-derived C-terminal peptides exert anti-inflammatory effects strictly through ChemR23, establishing the receptor as essential rather than redundant for resolution.","evidence":"In vivo zymosan peritonitis comparing wild-type and ChemR23-/- mice with neutralizing antibodies","pmids":["18391062"],"confidence":"High","gaps":["Cell type mediating anti-inflammatory effect not resolved","Signaling pathway downstream not defined"]},{"year":2009,"claim":"Defined chemerin processing requirements and ChemR23-dependent chemotaxis/calcium responses across pDC, mDC, macrophage and NK populations, generalizing the receptor's chemoattractant role across innate immune cells.","evidence":"Flow cytometry, calcium and chemotaxis assays in ChemR23 KO mice plus pharmacological analysis of prochemerin processing","pmids":["19841182"],"confidence":"High","gaps":["Identity of processing proteases not addressed","G protein subtype usage not specified"]},{"year":2009,"claim":"Extended CMKLR1 signaling to endothelium, linking inflammatory-cytokine-induced receptor upregulation to angiogenesis via PI3K/Akt and MAPK.","evidence":"Angiogenesis assays, gelatin zymography, and Western blot for PI3K/Akt and MAPK in human endothelial cells","pmids":["20044979"],"confidence":"Medium","gaps":["No genetic KO confirmation","Single lab","G protein coupling not tested"]},{"year":2010,"claim":"Placed CMKLR1 in a PPARγ-driven autocrine chemerin loop controlling the adipocyte-versus-osteoblast fate decision of stromal progenitors.","evidence":"siRNA knockdown, differentiation assays, and PPARγ overexpression rescue in primary bone marrow stromal cells","pmids":["19929432"],"confidence":"High","gaps":["Downstream signaling controlling fate not defined","In vivo relevance not tested in this study"]},{"year":2010,"claim":"Established CMKLR1 as a driver of macrophage phagocytosis and efferocytosis through Syk-dependent actin remodeling, defining a clearance function for the receptor.","evidence":"Phagocytosis/efferocytosis assays in ChemR23 KO macrophages with Syk inhibition, F-actin imaging, and in vivo peritoneal clearance","pmids":["20363975"],"confidence":"High","gaps":["Link between G protein signaling and Syk activation not resolved","Receptor-Syk physical coupling not shown"]},{"year":2010,"claim":"Showed chemerin-CMKLR1 drives a pro-inflammatory, catabolic program in chondrocytes via ERK and Akt, extending the receptor's signaling to cartilage pathology.","evidence":"Phospho-MAPK/Akt Western blots and cytokine/MMP measurement in primary human chondrocytes","pmids":["21192818"],"confidence":"Medium","gaps":["No genetic KO confirmation","Single lab","G protein dependence not established"]},{"year":2011,"claim":"Dissected opposing pro- and anti-inflammatory roles of ChemR23 in viral pneumonia, revealing leukocytic versus non-leukocytic compartments mediate distinct outcomes.","evidence":"ChemR23 KO mice, pneumovirus infection, pDC depletion, adoptive transfer, and chimeric mice","pmids":["22072972"],"confidence":"High","gaps":["Molecular nature of the non-leukocytic anti-inflammatory pathway undefined","Ligand driving each arm not separated"]},{"year":2011,"claim":"Established CMKLR1 as an in vivo regulator of adiposity, adipose immune composition, and glucose homeostasis, broadening its role from immunity into metabolism.","evidence":"CMKLR1 KO mouse body-composition, glucose tolerance/insulin secretion, immune flow cytometry, and tissue glucose uptake","pmids":["22186410"],"confidence":"High","gaps":["Cell-autonomous versus systemic contributions not separated","Signaling pathway mediating metabolic effects not defined"]},{"year":2013,"claim":"Showed CMKLR1 oligomerizes with CXCR4 and CCR7 with negative binding cooperativity, revealing cross-regulation of chemokine receptor systems at the membrane.","evidence":"BRET, HTRF, and radioligand competition assays validated in ChemR23 KO primary bone-marrow DCs","pmids":["23469143"],"confidence":"High","gaps":["Functional consequence of heteromerization in vivo not established","Single lab","Stoichiometry not defined"]},{"year":2013,"claim":"Defined a neutrophil-intrinsic C15/ChemR23 pathway that suppresses integrin activation and adhesion, providing a resolution mechanism protective in myocardial infarction.","evidence":"Granule localization imaging, integrin assays, intravital microscopy, and a murine MI model with ChemR23-dependent pharmacology","pmids":["23999103"],"confidence":"High","gaps":["Intracellular signaling linking receptor to integrin inactivation not mapped"]},{"year":2015,"claim":"Comprehensively defined CMKLR1 transduction: Gαi/o coupling, β-arrestin1/2 recruitment, and the dual Gαi/o + β-arrestin2 requirement for ERK, while distinguishing it from GPR1 and CCRL2.","evidence":"BRET biosensors for multiple G protein subtypes and β-arrestins, radioligand binding, and ERK phosphorylation with pathway inhibitors","pmids":["27716822"],"confidence":"High","gaps":["Structural basis of biased signaling not addressed","Receptor desensitization kinetics not in scope"]},{"year":2015,"claim":"Identified amyloid-β42 as a CMKLR1 ligand driving microglial migration and receptor internalization, linking the receptor to neuroinflammatory contexts.","evidence":"Binding in CMKLR1-transfected RBL cells, migration assays in microglia, pathway inhibitor studies, and internalization assays","pmids":["25079809"],"confidence":"Medium","gaps":["Single lab","Physiological relevance in brain not tested in vivo","Competition with chemerin not addressed"]},{"year":2015,"claim":"Mapped chemerin-CMKLR1 chemotaxis to a RhoA/ROCK/SRF and p38/Gαi/o axis, defining the cytoskeletal transcriptional output of the receptor.","evidence":"SRF/CRE/NF-κB luciferase reporters and pathway inhibitors with chemotaxis assays in L1.2 and AGS cells","pmids":["26363224"],"confidence":"Medium","gaps":["No genetic KO confirmation","Single lab","Species-specific differences not fully resolved"]},{"year":2015,"claim":"Revealed promoter-driven differential ChemR23 expression across M1/M2 macrophages and RvE1-driven resolution-type repolarization, connecting receptor regulation to macrophage programming.","evidence":"5' RACE promoter identification, flow cytometry, qPCR, chemotaxis, and phagocytosis in primary human macrophages","pmids":["25637017"],"confidence":"High","gaps":["Transcription factors driving P3 usage not fully identified"]},{"year":2016,"claim":"Demonstrated Gi-biased agonism at CMKLR1 mediating vasoconstriction and blood-pressure regulation, distinguishing its vascular pharmacology from GPR1.","evidence":"Vascular isometric tension, rat blood pressure, cAMP assays with selective antagonist CCX832, and immunohistochemistry","pmids":["27742615"],"confidence":"High","gaps":["Smooth-muscle contraction signaling downstream of Gi not fully mapped"]},{"year":2016,"claim":"Defined the chemerin/chemerin-9 binding epitope on ChemR23 using conformation-specific nanobody antagonists, providing tools and a structural footprint of the ligand site.","evidence":"Nanobody development, competition binding, calcium and chemotaxis assays in primary cells","pmids":["26864035"],"confidence":"High","gaps":["Atomic-resolution structure not determined","Single lab"]},{"year":2018,"claim":"Established that RvE1/ChemR23 restrains atherosclerosis by promoting macrophage clearance and limiting oxLDL uptake, defining an atheroprotective resolution axis.","evidence":"ChemR23/Apoe double KO mice, plaque histology, phagocytosis and oxLDL uptake assays, and plasma lipidomics","pmids":["29739755"],"confidence":"High","gaps":["Macrophage signaling linking receptor to oxLDL handling not fully resolved"]},{"year":2018,"claim":"Showed GRK6 phosphorylation and β-arrestin2 control CMKLR1 internalization and tune macrophage migration and AKT/ERK output, defining receptor desensitization machinery.","evidence":"BRET/co-IP arrestin recruitment, internalization flow cytometry, and GRK6 KO/β-arrestin2 KO primary macrophages with signaling Westerns","pmids":["30576947"],"confidence":"High","gaps":["Specific phosphorylation sites not mapped","Other GRK contributions not excluded"]},{"year":2018,"claim":"Identified a CMKLR1-PTEN-Akt axis through which chemerin suppresses hepatocellular carcinoma metastasis, revealing a tumor-suppressive receptor function.","evidence":"Co-IP of PTEN-CMKLR1, PTEN phosphatase/ubiquitination assays, and in vivo mouse metastasis models","pmids":["29717200"],"confidence":"High","gaps":["Mechanism of PTEN-receptor interaction control not fully resolved","Single lab"]},{"year":2018,"claim":"Linked chemerin-ChemR23 to keratinocyte inflammation via a ROS-sirt1-NF-κB pathway, connecting the receptor to psoriasis-like skin pathology.","evidence":"Cytokine ELISA, NF-κB/sirt1 Westerns, ROS measurement, and an imiquimod psoriasis model","pmids":["30426542"],"confidence":"Medium","gaps":["No genetic KO confirmation","Single lab","G protein dependence not tested"]},{"year":2019,"claim":"Identified CMKLR1 as a determinant of VSMC osteoblastic phenotype switching and phosphate-induced calcification, with RvE1 acting protectively through the receptor.","evidence":"ChemR23 KO mice and primary VSMCs, calcification assays, phenotype markers, vitamin D3 model, and Fat-1 transgene","pmids":["30597013"],"confidence":"High","gaps":["Opposing chemerin versus RvE1 effects on calcification not reconciled mechanistically"]},{"year":2019,"claim":"Showed chemerin via ChemR23 inhibits VSMC calcification by inducing matrix gla protein, indicating context-dependent receptor effects on vascular mineralization.","evidence":"Primary VSMC calcification assays in ChemR23 KO cells with MGP expression measurement","pmids":["31197872"],"confidence":"Medium","gaps":["Mechanistic depth limited","Single lab","Reconciliation with osteoblastic-phenotype findings unresolved"]},{"year":2019,"claim":"Established a required chemerin-CMKLR1 axis for NK cell recruitment to tumors, mediating the antitumor effects of all-trans retinoic acid.","evidence":"Chemerin KO and CMKLR1 KO melanoma tumor models with flow cytometry of tumor-infiltrating NK cells and atRA treatment","pmids":["31063220"],"confidence":"High","gaps":["Cellular source of chemerin in tumors not pinpointed","Direct NK chemotaxis versus indirect effects not fully separated"]},{"year":2019,"claim":"Defined hematopoietic ChemR23 as proatherogenic by restraining M2 polarization and cholesterol efflux and promoting pDC lesion accumulation, demonstrating cell-autonomous immune function.","evidence":"Hematopoietic-specific KO via bone marrow transplant, pDC adoptive transfer, histology, and flow cytometry in Apoe-/- mice","pmids":["30786742"],"confidence":"High","gaps":["Ligand (chemerin versus RvE1) driving this arm not separated","Reconciliation with protective RvE1/ChemR23 atherosclerosis role unresolved"]},{"year":2020,"claim":"Placed NLRP3 inflammasome activation downstream of chemerin-CMKLR1, linking the receptor to pyroptosis in diabetic cardiomyopathy.","evidence":"siRNA knockdown of CMKLR1 and NLRP3 in vivo and in vitro with epistasis, Western blots, and cell-death assays","pmids":["32390873"],"confidence":"Medium","gaps":["Knockdown only, no genetic KO","Single lab","Direct signaling link from receptor to NLRP3 not mapped"]},{"year":2020,"claim":"Extended the CMKLR1/PTEN axis to tumor immune evasion by showing chemerin suppresses PD-L1 via CMKLR1/PTEN/PI3K-AKT-mTOR signaling in prostate and sarcoma cells.","evidence":"CMKLR1 siRNA, pathway inhibitors, and forced-chemerin xenografts","pmids":["32605911"],"confidence":"Medium","gaps":["Single lab","Knockdown rather than KO","Direct receptor-PTEN coupling not re-demonstrated here"]},{"year":2020,"claim":"Demonstrated that ChemR23 is required for n-3 PUFA/RvE1-mediated protection against aortic valve stenosis, generalizing the resolution axis to valvular calcification.","evidence":"ChemR23 KO and Fat-1tg × Apoe-/- mice with echocardiography, histology, and lipidomics","pmids":["32506925"],"confidence":"High","gaps":["Cell type mediating valvular protection not pinpointed","Downstream signaling not dissected"]},{"year":2021,"claim":"Showed that agonist antibody engagement of ChemR23 is sufficient to drive efferocytosis and resolve chronic inflammation, validating the receptor as a therapeutic target.","evidence":"Agonist mAb characterization, efferocytosis and neutrophil-apoptosis assays, chronic colitis models, and IBD patient transcriptomics","pmids":["33811066"],"confidence":"High","gaps":["Receptor signaling triggered by the agonist mAb not fully mapped","Comparison to natural-ligand bias not addressed"]},{"year":2021,"claim":"Identified an adipocyte-autonomous CMKLR1 brake on cold-induced thermogenesis acting via cAMP-PKA-IL-33, linking the receptor to beige fat and type-2 immunity.","evidence":"Adipocyte-specific CMKLR1 KO mice, cold exposure, cAMP/PKA assays, IL-33 measurement, and metabolic phenotyping","pmids":["34330814"],"confidence":"High","gaps":["How Gi-coupled CMKLR1 dampens cAMP in adipocytes mechanistically detailed but ligand source in adipose not specified"]},{"year":2022,"claim":"Revealed an intestinal-epithelial CMKLR1-lactoperoxidase pathway restricting microbiota-driven neutrophilia and tumorigenesis, defining a non-hematopoietic protective function.","evidence":"IEC-specific CMKLR1 KO mice, microbiome and LPO analysis, neutrophil quantification, and LPO supplementation rescue","pmids":["35858331"],"confidence":"High","gaps":["Signaling linking receptor to LPO induction not mapped","Ligand driving epithelial CMKLR1 not identified"]},{"year":2022,"claim":"Showed chemerin stabilizes CMKLR1 against proteasomal degradation to amplify NF-κB-driven glioblastoma mesenchymal transition and M2 TAM polarization.","evidence":"Co-IP, ubiquitination assays, NF-κB reporter, expression manipulation, GBM xenografts, and macrophage polarization assays with α-NETA","pmids":["35459783"],"confidence":"Medium","gaps":["Single lab","Ubiquitin ligase regulating CMKLR1 not identified","Reconciliation with tumor-suppressive CMKLR1 roles unresolved"]},{"year":2023,"claim":"Defined an RvE1/ChemR23 AMPKα/Nrf2/NF-κB pathway in VSMCs that ameliorates hypertension and vascular remodeling, adding a metabolic-stress signaling output.","evidence":"AAV9 ChemR23 knockdown, Ang II hypertension model, signaling Westerns, blood pressure, and histology","pmids":["37800344"],"confidence":"Medium","gaps":["Knockdown rather than KO","Single lab","Direct receptor coupling to AMPKα not shown"]},{"year":2024,"claim":"Established CMKLR1 as a controller of lipid uptake and storage in clear-cell renal carcinoma through ATGL, SREBP1c, and CD36 regulation, with pharmacological inhibition triggering tumor cell death.","evidence":"Genetic and pharmacological (α-NETA) suppression, lipidomics/transcriptomics, PDX models, and ATGL/SREBP1c/CD36 Westerns","pmids":["38640229"],"confidence":"High","gaps":["Signaling chain linking the GPCR to SREBP1c/CD36 not fully mapped","Single lab"]},{"year":null,"claim":"How a single Gi/o-coupled receptor produces opposing outcomes—pro- versus anti-inflammatory, pro- versus anti-tumor, and pro- versus anti-calcific—depending on ligand (chemerin, RvE1, Aβ42), cell type, and signaling bias remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of CMKLR1 with distinct ligands","Ligand-specific biased signaling not mechanistically linked to divergent phenotypes","Endogenous source and processing of chemerin in each tissue context not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[4,16,17]},{"term_id":"GO:0001618","term_label":"virus receptor activity","supporting_discovery_ids":[1]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[16,20,14]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[16,18,20]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[5,9,11,19,27]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[12,34,38]}],"complexes":[],"partners":["RARRES2","CXCR4","CCR7","ARRB2","GRK6","PTEN"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99788","full_name":"Chemerin-like receptor 1","aliases":["Chemokine-like receptor 1","G-protein coupled receptor ChemR23","G-protein coupled receptor DEZ"],"length_aa":373,"mass_kda":42.3,"function":"Receptor for the chemoattractant adipokine chemerin/RARRES2 and for the omega-3 fatty acid derived molecule resolvin E1. Interaction with RARRES2 initiates activation of G proteins G(i)/G(o) and beta-arrestin pathways inducing cellular responses via second messenger pathways such as intracellular calcium mobilization, phosphorylation of MAP kinases MAPK1/MAPK3 (ERK1/2), TYRO3, MAPK14/P38MAPK and PI3K leading to multifunctional effects, like reduction of immune responses, enhancing of adipogenesis and angionesis (PubMed:27716822). Resolvin E1 down-regulates cytokine production in macrophages by reducing the activation of MAPK1/3 (ERK1/2) and NF-kappa-B. Positively regulates adipogenesis and adipocyte metabolism (Microbial infection) Acts as a coreceptor for several SIV strains (SIVMAC316, SIVMAC239, SIVMACL7E-FR and SIVSM62A), as well as a primary HIV-1 strain (92UG024-2)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/Q99788/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CMKLR1","classification":"Not Classified","n_dependent_lines":15,"n_total_lines":1208,"dependency_fraction":0.012417218543046357},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CMKLR1","total_profiled":1310},"omim":[{"mim_id":"608379","title":"CHEMOKINE, CC MOTIF, RECEPTOR-LIKE PROTEIN 2; CCRL2","url":"https://www.omim.org/entry/608379"},{"mim_id":"602351","title":"CHEMERIN CHEMOKINE-LIKE RECEPTOR 1; CMKLR1","url":"https://www.omim.org/entry/602351"},{"mim_id":"601973","title":"RETINOIC ACID RECEPTOR RESPONDER 2; RARRES2","url":"https://www.omim.org/entry/601973"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":32.3}],"url":"https://www.proteinatlas.org/search/CMKLR1"},"hgnc":{"alias_symbol":["RVER1","ERV1","ChemR23"],"prev_symbol":[]},"alphafold":{"accession":"Q99788","domains":[{"cath_id":"1.20.1070.10","chopping":"36-195_212-248_256-321","consensus_level":"medium","plddt":91.4009,"start":36,"end":321}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99788","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99788-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99788-F1-predicted_aligned_error_v6.png","plddt_mean":79.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CMKLR1","jax_strain_url":"https://www.jax.org/strain/search?query=CMKLR1"},"sequence":{"accession":"Q99788","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99788.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99788/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99788"}},"corpus_meta":[{"pmid":"17339491","id":"PMC_17339491","title":"Resolvin E1 selectively interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17339491","citation_count":496,"is_preprint":false},{"pmid":"18391062","id":"PMC_18391062","title":"Synthetic chemerin-derived peptides suppress inflammation through ChemR23.","date":"2008","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18391062","citation_count":311,"is_preprint":false},{"pmid":"20044979","id":"PMC_20044979","title":"Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20044979","citation_count":284,"is_preprint":false},{"pmid":"15728234","id":"PMC_15728234","title":"Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin.","date":"2005","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15728234","citation_count":238,"is_preprint":false},{"pmid":"19841182","id":"PMC_19841182","title":"Mouse ChemR23 is expressed in dendritic cell subsets and macrophages, and mediates an anti-inflammatory activity of chemerin in a lung disease model.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19841182","citation_count":209,"is_preprint":false},{"pmid":"9603476","id":"PMC_9603476","title":"ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains.","date":"1998","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9603476","citation_count":198,"is_preprint":false},{"pmid":"14675762","id":"PMC_14675762","title":"Characterization of human circulating TIG2 as a ligand for the orphan receptor ChemR23.","date":"2003","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/14675762","citation_count":167,"is_preprint":false},{"pmid":"29279348","id":"PMC_29279348","title":"International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Function.","date":"2017","source":"Pharmacological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29279348","citation_count":151,"is_preprint":false},{"pmid":"27716822","id":"PMC_27716822","title":"Signaling Properties of Chemerin Receptors CMKLR1, GPR1 and CCRL2.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27716822","citation_count":146,"is_preprint":false},{"pmid":"21056554","id":"PMC_21056554","title":"Chemokine-like receptor 1 (CMKLR1) and chemokine (C-C motif) receptor-like 2 (CCRL2); two multifunctional receptors with unusual properties.","date":"2010","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/21056554","citation_count":138,"is_preprint":false},{"pmid":"25637017","id":"PMC_25637017","title":"ChemR23, the receptor for chemerin and resolvin E1, is expressed and functional on M1 but not on M2 macrophages.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/25637017","citation_count":138,"is_preprint":false},{"pmid":"36614339","id":"PMC_36614339","title":"Correction: Chen et al. The Chemerin/CMKLR1 Axis Is Involved in the Recruitment of Microglia to Aβ Deposition through p38 MAPK Pathway. Int. J. Mol. Sci. 2022, 23, 9041.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36614339","citation_count":137,"is_preprint":false},{"pmid":"19929432","id":"PMC_19929432","title":"Role of chemerin/CMKLR1 signaling in adipogenesis and osteoblastogenesis of bone marrow stem cells.","date":"2010","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/19929432","citation_count":133,"is_preprint":false},{"pmid":"25548799","id":"PMC_25548799","title":"Chemerin/chemR23 axis in inflammation onset and resolution.","date":"2014","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/25548799","citation_count":132,"is_preprint":false},{"pmid":"22186410","id":"PMC_22186410","title":"Disruption of the chemokine-like receptor-1 (CMKLR1) gene is associated with reduced adiposity and glucose intolerance.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22186410","citation_count":132,"is_preprint":false},{"pmid":"29739755","id":"PMC_29739755","title":"ERV1/ChemR23 Signaling Protects Against Atherosclerosis by Modifying Oxidized Low-Density Lipoprotein Uptake and Phagocytosis in Macrophages.","date":"2018","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/29739755","citation_count":120,"is_preprint":false},{"pmid":"21192818","id":"PMC_21192818","title":"Human articular chondrocytes express ChemR23 and chemerin; ChemR23 promotes inflammatory signalling upon binding the ligand chemerin(21-157).","date":"2010","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21192818","citation_count":114,"is_preprint":false},{"pmid":"22072972","id":"PMC_22072972","title":"ChemR23 dampens lung inflammation and enhances anti-viral immunity in a mouse model of acute viral pneumonia.","date":"2011","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/22072972","citation_count":84,"is_preprint":false},{"pmid":"32390873","id":"PMC_32390873","title":"Chemerin/CMKLR1 Axis Promotes Inflammation and Pyroptosis by Activating NLRP3 Inflammasome in Diabetic Cardiomyopathy Rat.","date":"2020","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/32390873","citation_count":79,"is_preprint":false},{"pmid":"27742615","id":"PMC_27742615","title":"Chemerin Elicits Potent Constrictor Actions via Chemokine-Like Receptor 1 (CMKLR1), not G-Protein-Coupled Receptor 1 (GPR1), in Human and Rat Vasculature.","date":"2016","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/27742615","citation_count":79,"is_preprint":false},{"pmid":"21346723","id":"PMC_21346723","title":"The possible role of ChemR23/Chemerin axis in the recruitment of dendritic cells in lupus nephritis.","date":"2011","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/21346723","citation_count":74,"is_preprint":false},{"pmid":"26363224","id":"PMC_26363224","title":"CMKLR1 and GPR1 mediate chemerin signaling through the RhoA/ROCK pathway.","date":"2015","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26363224","citation_count":72,"is_preprint":false},{"pmid":"29090333","id":"PMC_29090333","title":"Resolvin E1/E2 ameliorate lipopolysaccharide-induced depression-like behaviors via ChemR23.","date":"2017","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29090333","citation_count":68,"is_preprint":false},{"pmid":"33811066","id":"PMC_33811066","title":"Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation resolution.","date":"2021","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/33811066","citation_count":65,"is_preprint":false},{"pmid":"24779513","id":"PMC_24779513","title":"Chemerin and CMKLR1 expression in human arteries and periadventitial fat: a possible role for local chemerin in atherosclerosis?","date":"2014","source":"BMC cardiovascular disorders","url":"https://pubmed.ncbi.nlm.nih.gov/24779513","citation_count":63,"is_preprint":false},{"pmid":"29717200","id":"PMC_29717200","title":"Chemerin suppresses hepatocellular carcinoma metastasis through CMKLR1-PTEN-Akt axis.","date":"2018","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29717200","citation_count":62,"is_preprint":false},{"pmid":"20363975","id":"PMC_20363975","title":"Chemerin peptides promote phagocytosis in a ChemR23- and Syk-dependent manner.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20363975","citation_count":60,"is_preprint":false},{"pmid":"25437209","id":"PMC_25437209","title":"A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory disease.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25437209","citation_count":60,"is_preprint":false},{"pmid":"32506925","id":"PMC_32506925","title":"Omega-3 Polyunsaturated Fatty Acids Decrease Aortic Valve Disease Through the Resolvin E1 and ChemR23 Axis.","date":"2020","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/32506925","citation_count":59,"is_preprint":false},{"pmid":"32605911","id":"PMC_32605911","title":"Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade.","date":"2020","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/32605911","citation_count":58,"is_preprint":false},{"pmid":"21430224","id":"PMC_21430224","title":"The role of ChemR23 in the induction and resolution of cigarette smoke-induced inflammation.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21430224","citation_count":56,"is_preprint":false},{"pmid":"30718467","id":"PMC_30718467","title":"Chemerin reverses neurological impairments and ameliorates neuronal apoptosis through ChemR23/CAMKK2/AMPK pathway in neonatal hypoxic-ischemic encephalopathy.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30718467","citation_count":55,"is_preprint":false},{"pmid":"26864035","id":"PMC_26864035","title":"Development by Genetic Immunization of Monovalent Antibodies (Nanobodies) Behaving as Antagonists of the Human ChemR23 Receptor.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26864035","citation_count":54,"is_preprint":false},{"pmid":"8976386","id":"PMC_8976386","title":"Molecular cloning of a novel receptor (CMKLR1) with homology to the chemotactic factor receptors.","date":"1996","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8976386","citation_count":53,"is_preprint":false},{"pmid":"36446229","id":"PMC_36446229","title":"ChemR23 signaling ameliorates cognitive impairments in diabetic mice via dampening oxidative stress and NLRP3 inflammasome activation.","date":"2022","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/36446229","citation_count":51,"is_preprint":false},{"pmid":"25079809","id":"PMC_25079809","title":"The chemerin receptor CMKLR1 is a functional receptor for amyloid-β peptide.","date":"2015","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/25079809","citation_count":48,"is_preprint":false},{"pmid":"30784180","id":"PMC_30784180","title":"Chemerin/ChemR23 axis promotes inflammation of glomerular endothelial cells in diabetic nephropathy.","date":"2019","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30784180","citation_count":48,"is_preprint":false},{"pmid":"34330814","id":"PMC_34330814","title":"The chemerin-CMKLR1 axis limits thermogenesis by controlling a beige adipocyte/IL-33/type 2 innate immunity circuit.","date":"2021","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34330814","citation_count":46,"is_preprint":false},{"pmid":"22118966","id":"PMC_22118966","title":"Adiponectin upregulates hepatocyte CMKLR1 which is reduced in human fatty liver.","date":"2011","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22118966","citation_count":46,"is_preprint":false},{"pmid":"27092781","id":"PMC_27092781","title":"The role of chemerin and ChemR23 in stimulating the invasion of squamous oesophageal cancer cells.","date":"2016","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27092781","citation_count":46,"is_preprint":false},{"pmid":"23999103","id":"PMC_23999103","title":"Chemerin15 inhibits neutrophil-mediated vascular inflammation and myocardial ischemia-reperfusion injury through ChemR23.","date":"2013","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/23999103","citation_count":45,"is_preprint":false},{"pmid":"29221117","id":"PMC_29221117","title":"Inhibition of chemerin/CMKLR1 axis in neuroblastoma cells reduces clonogenicity and cell viability in vitro and impairs tumor growth in vivo.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29221117","citation_count":42,"is_preprint":false},{"pmid":"24084834","id":"PMC_24084834","title":"ChemR23 knockout mice display mild obesity but no deficit in adipocyte differentiation.","date":"2013","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/24084834","citation_count":41,"is_preprint":false},{"pmid":"37800344","id":"PMC_37800344","title":"Resolvin E1/ChemR23 Protects Against Hypertension and Vascular Remodeling in Angiotensin II-Induced Hypertensive Mice.","date":"2023","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/37800344","citation_count":40,"is_preprint":false},{"pmid":"30597013","id":"PMC_30597013","title":"The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification.","date":"2019","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/30597013","citation_count":38,"is_preprint":false},{"pmid":"37932279","id":"PMC_37932279","title":"ChemR23 activation attenuates cognitive impairment in chronic cerebral hypoperfusion by inhibiting NLRP3 inflammasome-induced neuronal pyroptosis.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37932279","citation_count":37,"is_preprint":false},{"pmid":"30786742","id":"PMC_30786742","title":"Hematopoietic ChemR23 (Chemerin Receptor 23) Fuels Atherosclerosis by Sustaining an M1 Macrophage-Phenotype and Guidance of Plasmacytoid Dendritic Cells to Murine Lesions-Brief Report.","date":"2019","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30786742","citation_count":36,"is_preprint":false},{"pmid":"30426542","id":"PMC_30426542","title":"Chemerin/ChemR23 axis triggers an inflammatory response in keratinocytes through ROS-sirt1-NF-κB signaling.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30426542","citation_count":34,"is_preprint":false},{"pmid":"30719206","id":"PMC_30719206","title":"Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP-1 and TIMP-2.","date":"2019","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/30719206","citation_count":34,"is_preprint":false},{"pmid":"34398343","id":"PMC_34398343","title":"Chemerin promotes the pathogenesis of preeclampsia by activating CMKLR1/p-Akt/CEBPɑ axis and inducing M1 macrophage polarization.","date":"2021","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/34398343","citation_count":33,"is_preprint":false},{"pmid":"31399499","id":"PMC_31399499","title":"Chemerin-9, a potent agonist of chemerin receptor (ChemR23), prevents atherogenesis.","date":"2019","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/31399499","citation_count":32,"is_preprint":false},{"pmid":"32526705","id":"PMC_32526705","title":"Chemerin facilitates intervertebral disc degeneration via TLR4 and CMKLR1 and activation of NF-kB signaling pathway.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32526705","citation_count":32,"is_preprint":false},{"pmid":"22768214","id":"PMC_22768214","title":"The chemerin/ChemR23 system does not affect the pro-inflammatory response of mouse and human macrophages ex vivo.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22768214","citation_count":32,"is_preprint":false},{"pmid":"35459783","id":"PMC_35459783","title":"Chemerin enhances mesenchymal features of glioblastoma by establishing autocrine and paracrine networks in a CMKLR1-dependent manner.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35459783","citation_count":32,"is_preprint":false},{"pmid":"28625137","id":"PMC_28625137","title":"Chemokine Like Receptor-1 (CMKLR-1) Receptor: A Potential Therapeutic Target in Management of Chemerin Induced Type 2 Diabetes Mellitus and Cancer.","date":"2017","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/28625137","citation_count":32,"is_preprint":false},{"pmid":"29146976","id":"PMC_29146976","title":"Association of a variant in the gene encoding for ERV1/ChemR23 with reduced inflammation in visceral adipose tissue from morbidly obese individuals.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29146976","citation_count":32,"is_preprint":false},{"pmid":"31197872","id":"PMC_31197872","title":"Chemerin inhibits vascular calcification through ChemR23 and is associated with lower coronary calcium in chronic kidney disease.","date":"2019","source":"Journal of internal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31197872","citation_count":31,"is_preprint":false},{"pmid":"30595125","id":"PMC_30595125","title":"Parental Dietary Protein Source and the Role of CMKLR1 in Determining the Severity of Dahl Salt-Sensitive Hypertension.","date":"2019","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/30595125","citation_count":30,"is_preprint":false},{"pmid":"28670396","id":"PMC_28670396","title":"Effects of chemerin/CMKLR1 in obesity-induced hypertension and potential mechanism.","date":"2017","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/28670396","citation_count":30,"is_preprint":false},{"pmid":"22350950","id":"PMC_22350950","title":"Rosiglitazone ameliorates diabetic nephropathy by reducing the expression of Chemerin and ChemR23 in the kidney of streptozotocin-induced diabetic rats.","date":"2012","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/22350950","citation_count":30,"is_preprint":false},{"pmid":"26773141","id":"PMC_26773141","title":"Pro- and Anti-Inflammatory Role of ChemR23 Signaling in Pollutant-Induced Inflammatory Lung Responses.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26773141","citation_count":29,"is_preprint":false},{"pmid":"32630345","id":"PMC_32630345","title":"Chemerin Impairs In Vitro Testosterone Production, Sperm Motility, and Fertility in Chicken: Possible Involvement of Its Receptor CMKLR1.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32630345","citation_count":29,"is_preprint":false},{"pmid":"33144092","id":"PMC_33144092","title":"Chemerin/CMKLR1 ameliorates nonalcoholic steatohepatitis by promoting autophagy and alleviating oxidative stress through the JAK2-STAT3 pathway.","date":"2020","source":"Peptides","url":"https://pubmed.ncbi.nlm.nih.gov/33144092","citation_count":29,"is_preprint":false},{"pmid":"38640229","id":"PMC_38640229","title":"GPR1 and CMKLR1 Control Lipid Metabolism to Support the Development of Clear Cell Renal Cell Carcinoma.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38640229","citation_count":28,"is_preprint":false},{"pmid":"20663411","id":"PMC_20663411","title":"Cloning of porcine chemerin, ChemR23 and GPR1 and their involvement in regulation of lipogenesis.","date":"2010","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/20663411","citation_count":28,"is_preprint":false},{"pmid":"26893072","id":"PMC_26893072","title":"CMKLR1 deficiency maintains ovarian steroid production in mice treated chronically with dihydrotestosterone.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26893072","citation_count":28,"is_preprint":false},{"pmid":"30515096","id":"PMC_30515096","title":"Opposing Effects on Vascular Smooth Muscle Cell Proliferation and Macrophage-induced Inflammation Reveal a Protective Role for the Proresolving Lipid Mediator Receptor ChemR23 in Intimal Hyperplasia.","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30515096","citation_count":28,"is_preprint":false},{"pmid":"21542878","id":"PMC_21542878","title":"Chemerin/ChemR23 pathway: a system beyond chemokines.","date":"2011","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/21542878","citation_count":27,"is_preprint":false},{"pmid":"35317838","id":"PMC_35317838","title":"Role of Chemerin/ChemR23 axis as an emerging therapeutic perspective on obesity-related vascular dysfunction.","date":"2022","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35317838","citation_count":27,"is_preprint":false},{"pmid":"34461109","id":"PMC_34461109","title":"HOXA9-induced chemerin signals through CMKLR1/AMPK/TXNIP/NLRP3 pathway to induce pyroptosis of trophoblasts and aggravate preeclampsia.","date":"2021","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34461109","citation_count":27,"is_preprint":false},{"pmid":"22796467","id":"PMC_22796467","title":"Chronic mild restraint stress rats decreased CMKLR1 expression in distinct brain region.","date":"2012","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/22796467","citation_count":27,"is_preprint":false},{"pmid":"28326537","id":"PMC_28326537","title":"Gax suppresses chemerin/CMKLR1-induced preadipocyte biofunctions through the inhibition of Akt/mTOR and ERK signaling pathways.","date":"2017","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28326537","citation_count":27,"is_preprint":false},{"pmid":"37201735","id":"PMC_37201735","title":"Icosapent ethyl in cardiovascular prevention: Resolution of inflammation through the eicosapentaenoic acid - resolvin E1 - ChemR23 axis.","date":"2023","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/37201735","citation_count":25,"is_preprint":false},{"pmid":"30576947","id":"PMC_30576947","title":"Chemerin-activated functions of CMKLR1 are regulated by G protein-coupled receptor kinase 6 (GRK6) and β-arrestin 2 in inflammatory macrophages.","date":"2018","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30576947","citation_count":25,"is_preprint":false},{"pmid":"31588246","id":"PMC_31588246","title":"CMKLR1-targeting peptide tracers for PET/MR imaging of breast cancer.","date":"2019","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/31588246","citation_count":24,"is_preprint":false},{"pmid":"26972253","id":"PMC_26972253","title":"CMKLR1 deficiency influences glucose tolerance and thermogenesis in mice on high fat diet.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26972253","citation_count":24,"is_preprint":false},{"pmid":"36012305","id":"PMC_36012305","title":"The Chemerin/CMKLR1 Axis Is Involved in the Recruitment of Microglia to Aβ Deposition through p38 MAPK Pathway.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36012305","citation_count":24,"is_preprint":false},{"pmid":"35711300","id":"PMC_35711300","title":"The Chemerin-CMKLR1 Axis is Functionally important for Central Regulation of Energy Homeostasis.","date":"2022","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/35711300","citation_count":24,"is_preprint":false},{"pmid":"25699203","id":"PMC_25699203","title":"Evidence from studies in rodents and in isolated adipocytes that agonists of the chemerin receptor CMKLR1 may be beneficial in the treatment of type 2 diabetes.","date":"2015","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/25699203","citation_count":24,"is_preprint":false},{"pmid":"26265756","id":"PMC_26265756","title":"Local chemerin levels are positively associated with DSS-induced colitis but constitutive loss of CMKLR1 does not protect against development of colitis.","date":"2015","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/26265756","citation_count":24,"is_preprint":false},{"pmid":"35858331","id":"PMC_35858331","title":"Epithelial chemerin-CMKLR1 signaling restricts microbiota-driven colonic neutrophilia and tumorigenesis by up-regulating lactoperoxidase.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/35858331","citation_count":23,"is_preprint":false},{"pmid":"25049696","id":"PMC_25049696","title":"The Regulation of Chemerin and CMKLR1 Genes Expression by TNF-α, Adiponectin, and Chemerin Analog in Bovine Differentiated Adipocytes.","date":"2012","source":"Asian-Australasian journal of animal sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25049696","citation_count":23,"is_preprint":false},{"pmid":"30873215","id":"PMC_30873215","title":"Aerobic exercise decreases chemerin/CMKLR1 in the serum and peripheral metabolic organs of obesity and diabetes rats by increasing PPARγ.","date":"2019","source":"Nutrition & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/30873215","citation_count":23,"is_preprint":false},{"pmid":"23469143","id":"PMC_23469143","title":"Consequences of ChemR23 heteromerization with the chemokine receptors CXCR4 and CCR7.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23469143","citation_count":22,"is_preprint":false},{"pmid":"32398173","id":"PMC_32398173","title":"The expression of chemerin and its receptors (CMKLR1, GPR1, CCRL2) in the porcine uterus during the oestrous cycle and early pregnancy and in trophoblasts and conceptuses.","date":"2020","source":"Animal : an international journal of animal bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/32398173","citation_count":21,"is_preprint":false},{"pmid":"36626557","id":"PMC_36626557","title":"Molecular imaging of chemokine-like receptor 1 (CMKLR1) in experimental acute lung injury.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36626557","citation_count":20,"is_preprint":false},{"pmid":"32524150","id":"PMC_32524150","title":"Berberine attenuates non-alcoholic steatohepatitis by regulating chemerin/CMKLR1 signalling pathway and Treg/Th17 ratio.","date":"2020","source":"Naunyn-Schmiedeberg's archives of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32524150","citation_count":20,"is_preprint":false},{"pmid":"31926977","id":"PMC_31926977","title":"Assessment of CMKLR1 level in colorectal cancer and its correlation with angiogenic markers.","date":"2020","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31926977","citation_count":20,"is_preprint":false},{"pmid":"31063220","id":"PMC_31063220","title":"Chemerin partly mediates tumor-inhibitory effect of all-trans retinoic acid via CMKLR1-dependent natural killer cell recruitment.","date":"2019","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31063220","citation_count":20,"is_preprint":false},{"pmid":"16154247","id":"PMC_16154247","title":"Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens.","date":"2005","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/16154247","citation_count":20,"is_preprint":false},{"pmid":"38178174","id":"PMC_38178174","title":"ChemR23 signaling ameliorates brain injury via inhibiting NLRP3 inflammasome-mediated neuronal pyroptosis in ischemic stroke.","date":"2024","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38178174","citation_count":19,"is_preprint":false},{"pmid":"34605770","id":"PMC_34605770","title":"Involvement of chemerin and CMKLR1 in the progesterone decrease by PCOS granulosa cells.","date":"2021","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34605770","citation_count":19,"is_preprint":false},{"pmid":"29556954","id":"PMC_29556954","title":"Role of chemerin/CMKLR1 in the maintenance of early pregnancy.","date":"2018","source":"Frontiers of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29556954","citation_count":19,"is_preprint":false},{"pmid":"32814246","id":"PMC_32814246","title":"Expression of chemerin receptors CMKLR1, GPR1 and CCRL2 in the porcine pituitary during the oestrous cycle and early pregnancy and the effect of chemerin on MAPK/Erk1/2, Akt and AMPK signalling pathways.","date":"2020","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/32814246","citation_count":19,"is_preprint":false},{"pmid":"34029211","id":"PMC_34029211","title":"Curcumin inhibits the proliferation and migration of vascular smooth muscle cells by targeting the chemerin / CMKLR1 / LCN2 axis.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/34029211","citation_count":18,"is_preprint":false},{"pmid":"27881447","id":"PMC_27881447","title":"CMKLR1 activation ex vivo does not increase proportionally to serum total chemerin in obese humans.","date":"2016","source":"Endocrine connections","url":"https://pubmed.ncbi.nlm.nih.gov/27881447","citation_count":17,"is_preprint":false},{"pmid":"28905319","id":"PMC_28905319","title":"PI3K inhibition protects mice from NAFLD by down-regulating CMKLR1 and NLRP3 in Kupffer cells.","date":"2017","source":"Journal of physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28905319","citation_count":17,"is_preprint":false},{"pmid":"37539056","id":"PMC_37539056","title":"ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37539056","citation_count":16,"is_preprint":false},{"pmid":"33289084","id":"PMC_33289084","title":"Chemerin/ChemR23 regulates cementoblast function and tooth resorption in mice via inflammatory factors.","date":"2020","source":"Journal of periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/33289084","citation_count":16,"is_preprint":false},{"pmid":"21516134","id":"PMC_21516134","title":"Chemerin/ChemR23 signaling axis is involved in the endothelial protection by K(ATP) channel opener iptakalim.","date":"2011","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/21516134","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54911,"output_tokens":10494,"usd":0.161072,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21343,"output_tokens":9722,"usd":0.174882,"stage2_stop_reason":"end_turn"},"total_usd":0.335954,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"CMKLR1 (chemokine-like receptor 1) was cloned as a novel human gene encoding a seven-transmembrane G protein-linked receptor with 55% nucleotide homology to the IL-8 type 1 receptor and 53% to the N-formyl peptide related receptor 1, and was localized to human chromosome 12q24.1 by fluorescence in situ hybridization. mRNA is expressed in hematopoietic and immune tissues.\",\n      \"method\": \"Molecular cloning, FISH chromosomal mapping, Northern blot/expression analysis\",\n      \"journal\": \"Cytogenetics and cell genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct cloning and chromosomal localization by FISH, foundational study\",\n      \"pmids\": [\"8976386\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CMKLR1 (ChemR23) is expressed abundantly in monocyte-derived dendritic cells and macrophages and functions as a coreceptor for SIV strains (SIVmac316, SIVmac239, SIVmac17E-Fr, SIVsm62A) and a primary HIV-1 strain (92UG024-2) in cell fusion assays, but not for tested HIV-2 strains.\",\n      \"method\": \"RT-PCR expression analysis, cell fusion coreceptor assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct functional fusion assay with multiple viral strains, foundational characterization paper\",\n      \"pmids\": [\"9603476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TIG2 (chemerin, encoded by RARRES2) was identified as the natural ligand of CMKLR1 (ChemR23) through reverse pharmacology screening of a peptide library from human hemofiltrate; the active circulating form corresponds to amino acid residues 21–154 of the 163 aa prepropeptide.\",\n      \"method\": \"Reverse pharmacology peptide library screening, biochemical characterization\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct ligand identification by reverse pharmacology, endogenous peptide isolated and characterized\",\n      \"pmids\": [\"14675762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CMKLR1 (ChemR23) is expressed and functional on blood plasmacytoid and myeloid dendritic cells; recombinant chemerin induces transmigration of these cells across an endothelial cell monolayer. ChemR23 is expressed on the luminal side of high endothelial venules in secondary lymphoid organs, directing DC trafficking.\",\n      \"method\": \"Flow cytometry, transendothelial migration assay, immunohistochemistry\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional transmigration assay with primary cells plus in situ localization data, replicated across multiple tissue types\",\n      \"pmids\": [\"15728234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"RvE1 binds directly to CMKLR1 (ChemR23) on human PBMC and induces calcium mobilization; it also acts as a partial agonist at BLT1. At higher doses, RvE1's anti-inflammatory actions in vivo are BLT1-independent, consistent with ChemR23-mediated effects.\",\n      \"method\": \"[3H]RvE1 radioligand binding assay (membrane fractions), calcium mobilization assay, in vivo peritonitis model with BLT1 KO mice\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct radioligand binding with Kd determination, multiple orthogonal functional assays, genetic KO model\",\n      \"pmids\": [\"17339491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Proteolytically processed murine chemerin and derived C-terminal peptide chemerin15 (C15, residues A140–A154) exert anti-inflammatory effects entirely dependent on ChemR23; C15 suppressed neutrophil and monocyte recruitment in zymosan-induced peritonitis in wild-type but not ChemR23-/- mice, demonstrating absolute ChemR23 dependence.\",\n      \"method\": \"In vitro macrophage activation assay, in vivo peritonitis model using ChemR23 knockout mice, neutralizing antibody experiments\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout confirmation, multiple orthogonal in vivo and in vitro assays, replicated in two labs\",\n      \"pmids\": [\"18391062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Mouse CMKLR1 (ChemR23) is highly expressed on immature plasmacytoid DCs and at lower levels on myeloid DCs, macrophages, and NK cells. Chemerin promotes calcium mobilization and chemotaxis on these cells, and these responses are abrogated in ChemR23 knockout mice. Mouse prochemerin requires C-terminal processing to generate an active ChemR23 agonist.\",\n      \"method\": \"Flow cytometry, calcium mobilization assay, chemotaxis assay, ChemR23 KO mice, structural/pharmacological analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — functional assays with primary cells confirmed by genetic KO, multiple cell types and assays\",\n      \"pmids\": [\"19841182\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CMKLR1 (ChemR23) is expressed in human endothelial cells and is upregulated by pro-inflammatory cytokines TNF-α, IL-1β, and IL-6. Chemerin acting via ChemR23 induces endothelial angiogenesis, MMP-2 and MMP-9 gelatinolytic activity, and dose-dependently activates PI3K/Akt and MAPK signaling pathways.\",\n      \"method\": \"In vitro angiogenesis assays, gelatin zymography, Western blot for PI3K/Akt and MAPK phosphorylation\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple functional assays in a single lab, no genetic KO confirmation\",\n      \"pmids\": [\"20044979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Knockdown of CMKLR1 by RNA interference abrogated adipocyte differentiation, clonal expansion, and basal proliferation of bone marrow stromal cells (BMSCs), and was associated with increased osteoblast marker gene expression and mineralization. Forced PPARγ expression induced chemerin and partially rescued loss of adipogenesis caused by CMKLR1 knockdown, placing CMKLR1 downstream of PPARγ in a chemerin autocrine loop.\",\n      \"method\": \"siRNA knockdown, adipogenesis/osteoblastogenesis differentiation assays, PPARγ overexpression rescue, primary BMSC cultures\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA knockdown with multiple orthogonal differentiation readouts and genetic rescue experiment in primary cells\",\n      \"pmids\": [\"19929432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CMKLR1 (ChemR23) promotes phagocytosis of microbial particles and efferocytosis of apoptotic cells in macrophages by a mechanism involving increased actin polymerization and F-actin localization to the phagocytic cup in a Syk kinase-dependent manner; these prophagocytic effects are absent in ChemR23-/- macrophages and completely abrogated by pharmacological Syk inhibition.\",\n      \"method\": \"Phagocytosis/efferocytosis assays, ChemR23 KO macrophages, pharmacological Syk inhibition, F-actin imaging, in vivo peritoneal clearance assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO and pharmacological inhibition combined, multiple orthogonal assays, in vitro and in vivo confirmation\",\n      \"pmids\": [\"20363975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Chemerin stimulation of human articular chondrocytes via ChemR23 activates ERK1/2 (p44/p42 MAPK) and Akt (Ser473) phosphorylation and significantly increases secretion of pro-inflammatory cytokines (IL-6, IL-8, TNF-α, IL-1β) and matrix metalloproteases (MMP-1, MMP-2, MMP-3, MMP-8, MMP-13).\",\n      \"method\": \"Western blot for phospho-MAPK and phospho-Akt, cytokine ELISA, MMP measurement in cell supernatants, primary chondrocyte cultures\",\n      \"journal\": \"Arthritis research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple signaling and functional readouts, single lab, no genetic KO confirmation\",\n      \"pmids\": [\"21192818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ChemR23 deficiency in mice leads to reduced plasmacytoid DC recruitment to lungs during viral pneumonia, decreased type I interferon production, and increased neutrophilic infiltration, demonstrating a dual role: ChemR23-dependent pDC recruitment contributes to viral clearance but also promotes inflammation, while a separate ChemR23-dependent anti-inflammatory pathway in non-leukocytic cells reduces morbidity/mortality.\",\n      \"method\": \"ChemR23 KO mice, PVM infection model, pDC depletion, adoptive transfer, chimeric mice\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models including KO, depletion, adoptive transfer, and chimeras; multiple orthogonal readouts\",\n      \"pmids\": [\"22072972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CMKLR1 (ChemR23) deficiency in mice results in reduced adiposity (lower body mass and percent body fat), decreased hepatic dendritic cell infiltration, decreased adipose CD3+ T cells, increased adipose NK cells, and impaired glucose-stimulated insulin secretion and glucose uptake in skeletal muscle and white adipose tissue, establishing CMKLR1 as a regulator of adipose development, inflammation, and glucose homeostasis in vivo.\",\n      \"method\": \"CMKLR1 KO mouse model, body composition analysis, glucose tolerance/insulin secretion tests, flow cytometry of immune infiltrates, tissue glucose uptake assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — comprehensive KO phenotyping with multiple orthogonal metabolic and immunological readouts\",\n      \"pmids\": [\"22186410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ChemR23 forms homomers and heteromers with chemokine receptors CCR7 and CXCR4 as demonstrated by BRET and HTRF assays. Negative binding cooperativity was detected between ChemR23 and these chemokine receptors: ligands of one receptor competed for binding of a tracer to the other. In primary mouse bone marrow-derived DCs from wild-type vs ChemR23 KO mice, ChemR23-specific ligands cross-inhibited CXCL12 binding on CXCR4 in a ChemR23-dependent manner.\",\n      \"method\": \"BRET assay, HTRF assay, radioligand binding competition, ChemR23 KO bone marrow-derived DCs\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — BRET and HTRF for heteromerization, validated with genetic KO primary cells, single lab\",\n      \"pmids\": [\"23469143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ChemR23 is expressed in neutrophil granules and is rapidly upregulated upon neutrophil activation. The C15/ChemR23 pathway inhibits integrin activation and clustering, reduces neutrophil adhesion and chemotaxis in vitro, and induces adherent cell detachment from inflamed endothelium in vivo, reducing neutrophil recruitment and heart damage in a murine myocardial infarction model through ChemR23.\",\n      \"method\": \"Flow cytometry, immunofluorescence (granule localization), integrin activation assays, intravital microscopy, murine MI model, ChemR23-dependent pharmacological experiments\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — subcellular localization established, multiple functional assays in vitro and in vivo with ChemR23-dependent mechanism confirmed\",\n      \"pmids\": [\"23999103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CMKLR1 small molecule antagonist α-NETA inhibits chemerin-stimulated β-arrestin2 association with CMKLR1 and chemerin-triggered CMKLR1+ cell migration, and significantly delayed EAE onset and reduced CNS mononuclear cell infiltrates when administered to mice, pharmacologically recapitulating the CMKLR1 KO phenotype.\",\n      \"method\": \"β-arrestin2 recruitment assay, cell migration assay, EAE model (active immunization and adoptive transfer), CNS histology\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — mechanistic assays for β-arrestin recruitment and migration plus in vivo EAE model, single lab\",\n      \"pmids\": [\"25437209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Chemerin binds to CMKLR1 (and GPR1 and CCRL2) with low nanomolar affinity. Binding of chemerin and the chemerin-9 nonapeptide (149YFPGQFAFS157) to CMKLR1 activates Gαi1, Gαi2, Gαi3, Gαoa, and Gαob (but not Gαs or Gαq), and recruits β-arrestin1 and β-arrestin2. ERK1/2 phosphorylation requires both Gαi/o and β-arrestin2 but not β-arrestin1. GPR1 does not activate G proteins but does recruit β-arrestins. CCRL2 does not activate G proteins or recruit β-arrestins.\",\n      \"method\": \"BRET-based biosensors for G protein activation and β-arrestin recruitment, radioligand binding, ERK phosphorylation with pathway-specific inhibitors\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — BRET biosensors for multiple G protein subtypes, multiple orthogonal methods including binding and downstream signaling, comprehensive pharmacological dissection\",\n      \"pmids\": [\"27716822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CMKLR1 is a functional receptor for amyloid-β peptide (Aβ42): Aβ42 binds specifically to CMKLR1 in stably transfected RBL cells, induces CMKLR1-dependent cell migration via ERK1/2, PKA, and Akt pathways (but not Ca2+ mobilization), and stimulates internalization of the Aβ42-CMKLR1 complex in microglia and CMKLR1-RBL cells.\",\n      \"method\": \"Radioligand-equivalent binding in stably transfected RBL cells, migration assays (N9 microglia, primary microglia, CMKLR1-RBL vs untransfected RBL), pathway inhibitor studies, internalization assay\",\n      \"journal\": \"Journal of Alzheimer's disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — specific binding and migration shown with CMKLR1-expressing vs non-expressing cells, multiple pathway readouts, single lab\",\n      \"pmids\": [\"25079809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CMKLR1 signals through a RhoA/ROCK-dependent pathway to activate the transcriptional regulator SRF; chemerin-mediated chemotaxis requires p38, Gαi/o, RhoA, and ROCK signaling. Species-specific and receptor-dependent differences in GPR1 and CMKLR1 signaling were demonstrated.\",\n      \"method\": \"Luciferase reporter assays (SRF, CRE, NF-κB), pathway-specific inhibitors, chemotaxis assay in L1.2 and AGS cells\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple reporter assays and pharmacological inhibition, single lab, no genetic KO confirmation\",\n      \"pmids\": [\"26363224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"ChemR23 is differentially expressed in macrophage polarization states: LPS or IFN-γ stimulation increases transcription from promoter P3 in M1 macrophages. M1 macrophages expressing ChemR23 are chemotactic to chemerin, while M2 macrophages without surface ChemR23 are not. RvE1 (10 nM) acting through ChemR23 on M1 macrophages increases IL-10 transcription and phagocytosis of microbial particles, driving resolution-type repolarization.\",\n      \"method\": \"5' RACE (promoter identification), flow cytometry, qPCR, chemotaxis assay, phagocytosis assay, primary human macrophages\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — 5' RACE for promoter characterization, multiple functional assays (chemotaxis, phagocytosis, cytokine measurement) in primary human cells, mechanistic promoter analysis\",\n      \"pmids\": [\"25637017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Chemerin exerts vasoconstrictor actions via CMKLR1 but not GPR1 in human and rat vasculature: the chemerin C-terminal peptide C9 (chemerin149-157) contracted human saphenous vein and resistance arteries and increased blood pressure in rats, and these effects were blocked by the selective CMKLR1 antagonist CCX832. C9 inhibited cAMP accumulation in human aortic smooth muscle cells and showed ~5000-fold bias toward Gi protein signaling over other pathways (biased agonism at CMKLR1).\",\n      \"method\": \"Isometric tension (vascular contraction), blood pressure measurement in rats, cAMP accumulation assay, selective antagonist CCX832, immunohistochemistry for receptor localization\",\n      \"journal\": \"Journal of the American Heart Association\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct functional pharmacology with selective antagonist, multiple vascular preparations, in vivo confirmation, receptor localization\",\n      \"pmids\": [\"27742615\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Nanobodies (CA4910 and CA5183) targeting the native conformation of ChemR23 bind to a site overlapping with the chemerin binding site and act as antagonists of chemerin-induced intracellular calcium increase and chemotaxis of human primary cells. A bivalent CA4910 nanobody showed enhanced antagonist efficacy. The chemerin C-terminal nonapeptide (chemerin149-157) binding site on ChemR23 largely overlaps with the chemerin binding site.\",\n      \"method\": \"Phage display/genetic immunization (nanobody development), competition binding assays, calcium mobilization assay, chemotaxis assay, flow cytometry with primary cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — competition binding defines overlapping binding sites, multiple functional assays in transfected and primary cells, bivalent construct validates specificity\",\n      \"pmids\": [\"26864035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Targeted deletion of the resolvin E1 receptor Erv1/ChemR23 in hyperlipidemic mice (Apoe-/-) leads to proatherogenic macrophage signaling, increased oxidized LDL uptake, reduced phagocytosis, and increased atherosclerotic plaque size and necrotic core formation. RvE1-mediated effects on oxLDL uptake and phagocytosis in macrophages are dependent on Erv1/ChemR23.\",\n      \"method\": \"ChemR23/Apoe double KO mice, histological plaque analysis, macrophage phagocytosis assay, oxLDL uptake assay, lipidomic plasma analysis\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO model with multiple functional macrophage assays and in vivo atherosclerosis outcome, independent validation in two hyperlipidemic mouse models\",\n      \"pmids\": [\"29739755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Chemerin-activated CMKLR1 signaling in inflammatory macrophages is regulated by GRK6-mediated phosphorylation and β-arrestin 2 recruitment: co-expression of GRK6 enhances β-arrestin recruitment to CMKLR1 after chemerin stimulation; GRK6- and β-arrestin 2-deficient macrophages show decreased CMKLR1 internalization, increased migration toward chemerin, and altered AKT and ERK signaling.\",\n      \"method\": \"BRET/co-IP β-arrestin recruitment assay, flow cytometry internalization assay, GRK6 KO and β-arrestin 2 KO primary macrophages, migration assay, Western blot (AKT, ERK)\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO macrophages combined with overexpression and multiple signaling readouts, mechanistic dissection of GRK/arrestin regulation\",\n      \"pmids\": [\"30576947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Chemerin suppresses HCC metastasis through a CMKLR1-PTEN-Akt signaling axis: chemerin interferes with the PTEN-CMKLR1 protein interaction (shown by immunoprecipitation), upregulates PTEN expression and phosphatase activity, reduces PTEN ubiquitination, and decreases p-Akt (Ser473), thereby suppressing HCC cell migration and invasion.\",\n      \"method\": \"Co-immunoprecipitation, forced expression/RNAi, PTEN phosphatase activity assay, ubiquitination assay, Western blot, in vivo mouse metastasis models\",\n      \"journal\": \"British journal of cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — co-IP demonstrates PTEN-CMKLR1 interaction, multiple orthogonal assays (phosphatase activity, ubiquitination, in vivo), single lab\",\n      \"pmids\": [\"29717200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Chemerin acting via ChemR23 in keratinocytes triggers inflammatory responses through a ROS-sirt1-NF-κB signaling pathway: chemerin increases ROS production, suppresses sirt1 expression and deacetylase activity, leading to increased NF-κB p65 acetylation and activation, and enhanced secretion of inflammatory cytokines.\",\n      \"method\": \"ELISA (cytokines), Western blot (NF-κB, sirt1), ROS measurement, in vivo imiquimod mouse psoriasis model\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — multiple signaling readouts with receptor-dependent mechanism, in vivo model, single lab\",\n      \"pmids\": [\"30426542\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CMKLR1 in vascular smooth muscle cells (VSMCs) acts as a determinant of synthetic and osteoblastic phenotype, promoting phosphate-induced calcification: ChemR23-deficient VSMCs maintain a non-synthetic phenotype and resist phosphate-induced calcification; ChemR23-deficient mice are protected against vitamin D3-induced vascular calcification. Resolvin E1 inhibits VSMC calcification through ChemR23.\",\n      \"method\": \"ChemR23 KO mice, primary VSMC isolation, calcification assays, phenotype marker gene expression, in vivo vitamin D3 calcification model, Fat-1 transgene experiments\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO primary cells and in vivo model, multiple orthogonal functional assays, ChemR23-dependent rescue with RvE1\",\n      \"pmids\": [\"30597013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Chemerin recruits NK cells to the tumor microenvironment via CMKLR1: CMKLR1-/- and chemerin-/- (Rarres2-/-) mice showed impaired tumor-infiltrating NK cells in murine melanoma models, and the NK cell-enhancing and tumor-inhibitory effects of all-trans retinoic acid were completely abrogated in both Rarres2-/- and Cmklr1-/- mice, demonstrating a required chemerin-CMKLR1 axis for NK cell recruitment.\",\n      \"method\": \"Chemerin KO and CMKLR1 KO mouse tumor models, flow cytometry of tumor-infiltrating NK cells, atRA treatment\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent genetic KO models (ligand and receptor) both ablate the same phenotype, in vivo tumor model\",\n      \"pmids\": [\"31063220\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Chemerin inhibits vascular calcification through ChemR23 in VSMCs: chemerin reduces phosphate-induced calcification and increases matrix gla protein (MGP) expression in wild-type VSMCs but is devoid of these effects in VSMCs lacking ChemR23.\",\n      \"method\": \"Primary VSMC calcification assay, ChemR23 KO VSMCs, MGP expression measurement\",\n      \"journal\": \"Journal of internal medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO cells confirm receptor dependence, single lab, limited mechanistic depth\",\n      \"pmids\": [\"31197872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ChemR23 (CMKLR1) deficiency in hematopoietic cells reduces atherosclerosis by promoting M2 macrophage polarization, increasing cholesterol efflux, and reducing pDC frequency and their migration to atherosclerotic lesions. ChemR23-deficient pDCs show reduced migratory capacity and decreased CCR7 expression; adoptive transfer confirmed reduced accumulation of ChemR23-KO pDCs in lesions.\",\n      \"method\": \"ChemR23 KO/knockin eGFP reporter mice crossed to Apoe-/- mice, bone marrow transplantation (hematopoietic KO), pDC adoptive transfer, histology, flow cytometry, gene expression\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — hematopoietic-specific KO and adoptive transfer experiments establish cell-autonomous function, multiple orthogonal readouts\",\n      \"pmids\": [\"30786742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The chemerin/CMKLR1 axis promotes inflammation and pyroptosis in diabetic cardiomyopathy through NLRP3 inflammasome activation: CMKLR1 siRNA attenuated NLRP3 expression, caspase-1 activation, IL-1β maturation, and pyroptosis in vivo. In vitro, silencing either CMKLR1 or NLRP3 suppressed activated caspase-1, IL-1β, and pyroptosis, and combined silencing further decreased IL-1β and pyroptosis, indicating NLRP3 acts downstream of CMKLR1.\",\n      \"method\": \"siRNA knockdown (CMKLR1, NLRP3) in vivo and in vitro, Western blot, LDH/EthD-III cell death assays, cardiac function measurement\",\n      \"journal\": \"Frontiers in physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — epistasis established by double KD, multiple readouts, single lab\",\n      \"pmids\": [\"32390873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Chemerin upregulates PTEN expression/activity and suppresses PD-L1 expression in prostate and sarcoma tumor cells via a CMKLR1/PTEN/PD-L1 signaling cascade: CMKLR1 knockdown abrogated both chemerin-induced PTEN upregulation and PD-L1 suppression; PI3K/AKT/mTOR pathway inhibitors mimicked these effects, and forced chemerin expression in DU145 xenografts increased PTEN and decreased PD-L1 in vivo.\",\n      \"method\": \"siRNA knockdown of CMKLR1, Western blot, specific pathway inhibitors, in vivo xenograft model with forced chemerin expression\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — receptor knockdown plus in vivo confirmation, multiple tumor types, single lab\",\n      \"pmids\": [\"32605911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"n-3 PUFA-derived resolvin E1 and its receptor ChemR23 constitute a key axis restricting aortic valve stenosis progression: abrogation of ChemR23 enhanced disease progression, and the beneficial effects of endogenous n-3 PUFA synthesis (Fat-1 transgene) were abolished in the absence of ChemR23, establishing a required role for ChemR23 in RvE1-mediated inhibition of valvular calcification.\",\n      \"method\": \"ChemR23 KO mice, Fat-1tg × Apoe-/- mice, echocardiography, histology, lipidomics (LC-MS/MS)\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO epistasis with two independent mouse models, functional echocardiographic and histological outcomes, lipidomic validation\",\n      \"pmids\": [\"32506925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"An agonist anti-ChemR23 monoclonal antibody induces ChemR23 receptor signaling, promotes macrophage efferocytosis, and reduces neutrophil tissue accumulation. In ongoing chronic colitis models, the antibody triggered resolution with decreased tissue lesions, fibrosis, and inflammation-driven tumors, demonstrating that GPCR agonism at ChemR23 is sufficient to drive resolution of chronic inflammation.\",\n      \"method\": \"Agonist mAb characterization, efferocytosis assay, neutrophil apoptosis assay, chronic colitis mouse models, transcriptional analysis in IBD patients\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — novel agonist antibody with mechanistic in vitro validation (efferocytosis, receptor signaling) and in vivo disease model, multiple endpoints\",\n      \"pmids\": [\"33811066\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The chemerin-CMKLR1 axis restricts cold-induced thermogenesis and beige fat formation by dampening cAMP-PKA signaling in adipocytes, thereby reducing IL-33 production from beige adipocytes and interrupting a feed-forward circuit between beige adipocytes and type 2 innate immunity. Adipocyte-specific CMKLR1 deletion enhanced beige fat and thermogenesis and protected against diet-induced obesity.\",\n      \"method\": \"Adipocyte-specific CMKLR1 knockout mice, cold exposure experiments, cAMP/PKA signaling assays, IL-33 measurement, type 2 innate immune cell analysis, metabolic phenotyping\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional cell-type-specific KO identifies adipocyte-autonomous mechanism, cAMP-PKA signaling dissected, multiple orthogonal readouts\",\n      \"pmids\": [\"34330814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The chemerin-CMKLR1 axis in intestinal epithelial cells (IECs) restricts microbiota-driven colonic neutrophilia and tumorigenesis by upregulating lactoperoxidase (LPO): IEC-specific CMKLR1 deletion reduced LPO expression, causing outgrowth of gram-negative bacteria and dysregulated CXCL1/2-mediated neutrophilia; LPO supplementation fully rescued these phenotypes.\",\n      \"method\": \"Intestinal epithelial cell-specific CMKLR1 KO mice, LPO expression analysis, microbiome analysis, neutrophil quantification, LPO supplementation rescue experiment\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with genetic rescue (LPO supplementation), mechanistic pathway identification, multiple orthogonal readouts\",\n      \"pmids\": [\"35858331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Chemerin enhances mesenchymal features of glioblastoma cells through a CMKLR1-dependent mechanism: chemerin suppresses ubiquitin-proteasomal degradation of CMKLR1, thereby enhancing NF-κB pathway activation; this CMKLR1/NF-κB axis also drives M2 polarization of tumor-associated macrophages and their mesenchymal phenotype-promoting ability. α-NETA blockade disrupted this network.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, NF-κB reporter, CMKLR1 overexpression/knockdown, GBM xenograft models, macrophage polarization assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — ubiquitination and co-IP establish mechanism, multiple cell models and in vivo xenograft, single lab\",\n      \"pmids\": [\"35459783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"RvE1/ChemR23 ameliorates hypertension and vascular remodeling by activating AMPKα/Nrf2 signaling: RvE1 inhibited Ccl5 expression in VSMCs via AMPKα/Nrf2/canonical NF-κB pathway (reducing immune cell infiltration) and regulated VSMC phenotypic transformation and proliferation. All effects were reversed by ChemR23 knockdown (AAV9-shRNA).\",\n      \"method\": \"AAV9-mediated ChemR23 knockdown, Ang II hypertension mouse model, Western blot (AMPKα, Nrf2, NF-κB), blood pressure measurement, histology, qPCR\",\n      \"journal\": \"Hypertension\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — receptor knockdown confirms ChemR23 dependence, signaling pathway dissected, single lab\",\n      \"pmids\": [\"37800344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CMKLR1 controls lipid metabolism in clear cell renal cell carcinoma (ccRCC): genetic or pharmacological suppression of CMKLR1 reduced lipid formation and induced apoptosis, ferroptosis, and autophagy. Mechanistically, CMKLR1 suppresses adipose triglyceride lipase (ATGL) and uniquely controls lipid uptake through regulation of sterol regulatory element-binding protein 1c (SREBP1c) and the CD36 scavenger receptor; α-NETA treatment dramatically reduced tumor growth and lipid storage in patient-derived xenograft models.\",\n      \"method\": \"Genetic knockdown/knockout and pharmacological inhibition (α-NETA), lipidomic and transcriptomic profiling, patient-derived xenograft models, Western blot for ATGL/SREBP1c/CD36\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — comprehensive lipidomics + transcriptomics + in vivo PDX models + mechanistic molecular targets identified, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"38640229\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CMKLR1 (ChemR23) is a seven-transmembrane Gi/o-coupled GPCR that binds chemerin (TIG2/RARRES2) and resolvin E1 as principal ligands, and also functions as a receptor for amyloid-β42; ligand binding activates Gαi1/2/3 and Gαo isoforms, recruits β-arrestin1/2 (regulated by GRK6-mediated phosphorylation), triggers RhoA/ROCK/SRF, MAPK/ERK, PI3K/Akt, and AMPKα/Nrf2 downstream signaling cascades, forms homomers and heteromers with CXCR4 and CCR7 with negative binding cooperativity, and controls diverse cellular processes including dendritic cell and NK cell chemotaxis, neutrophil granule exocytosis and adhesion, macrophage phagocytosis/efferocytosis and polarization, adipogenesis/thermogenesis, vascular smooth muscle calcification and contraction, and lipid metabolism in cancer cells—with these functions established through genetic knockout models, direct binding assays, and pharmacological dissection across multiple tissues.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CMKLR1 (ChemR23) is a seven-transmembrane G protein-coupled receptor, cloned from human chromosome 12q24.1 and expressed in hematopoietic and immune tissues, that orchestrates leukocyte trafficking, inflammation resolution, and tissue metabolism [#0, #2]. Its principal endogenous ligand is chemerin (TIG2/RARRES2), identified by reverse pharmacology, whose active forms require C-terminal proteolytic processing to generate ChemR23 agonists [#2, #6]; the receptor also binds the proresolving lipid mediator resolvin E1 and the amyloid-\\u03b242 peptide [#4, #17]. Chemerin engagement of CMKLR1 activates G\\u03b1i/o isoforms (not G\\u03b1s or G\\u03b1q) and recruits \\u03b2-arrestin1/2, with ERK1/2 phosphorylation requiring both G\\u03b1i/o and \\u03b2-arrestin2; receptor desensitization and internalization are controlled by GRK6-mediated phosphorylation [#16, #23]. Downstream the receptor drives RhoA/ROCK/SRF, PI3K/Akt, and MAPK cascades to direct chemotaxis [#7, #18], and it can signal in a strongly Gi-biased manner to mediate vasoconstriction [#20]. Through these pathways CMKLR1 controls dendritic-cell, NK-cell, and macrophage recruitment and function, including macrophage phagocytosis/efferocytosis via a Syk-dependent actin-remodeling mechanism and M1/M2 polarization [#3, #9, #19, #27]. The chemerin/RvE1-CMKLR1 axis is a major node in inflammation resolution and cardiometabolic biology: it limits neutrophil recruitment and adhesion in myocardial infarction, restrains atherosclerosis and vascular/valvular calcification, regulates adipogenesis, glucose homeostasis, and cold-induced thermogenesis, and modulates tumor immunity and cancer-cell lipid metabolism [#5, #12, #22, #26, #34, #38]. CMKLR1 additionally forms homomers and heteromers with CXCR4 and CCR7 with negative binding cooperativity [#13].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established the molecular identity of CMKLR1 as a candidate chemoattractant GPCR, defining the gene and its genomic location before any ligand was known.\",\n      \"evidence\": \"Molecular cloning, FISH chromosomal mapping, and Northern expression analysis of the human gene\",\n      \"pmids\": [\"8976386\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No ligand identified\", \"Signaling mechanism unknown\", \"Function inferred only from homology to chemokine/formyl-peptide receptors\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed the orphan receptor was expressed on dendritic cells and macrophages and could serve as a viral fusion coreceptor, linking it to immune cells before its physiological ligand was defined.\",\n      \"evidence\": \"RT-PCR expression analysis and cell fusion coreceptor assays with SIV and HIV-1 strains\",\n      \"pmids\": [\"9603476\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous ligand still unknown\", \"Physiological role of coreceptor activity unclear\", \"No signaling characterization\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Deorphanized the receptor by identifying chemerin (TIG2/RARRES2) as its natural ligand, converting CMKLR1 into a defined signaling system.\",\n      \"evidence\": \"Reverse pharmacology screening of a human hemofiltrate peptide library with biochemical characterization of the active 21\\u2013154 form\",\n      \"pmids\": [\"14675762\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"G protein coupling not yet defined\", \"Downstream effectors unknown\", \"Processing requirements for activity not yet resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated that chemerin-CMKLR1 directs functional trafficking of plasmacytoid and myeloid dendritic cells, establishing a bona fide chemoattractant role in immune cell positioning.\",\n      \"evidence\": \"Flow cytometry, transendothelial migration assays with primary DCs, and immunohistochemistry of high endothelial venules\",\n      \"pmids\": [\"15728234\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling cascade driving migration not dissected\", \"In vivo trafficking not yet confirmed genetically\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified resolvin E1 as a second direct ligand acting through CMKLR1, connecting the receptor to active resolution of inflammation distinct from its chemerin function.\",\n      \"evidence\": \"[3H]RvE1 radioligand binding on human PBMC membranes, calcium mobilization, and in vivo peritonitis with BLT1 KO mice\",\n      \"pmids\": [\"17339491\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific RvE1 effects not separated from BLT1\", \"Downstream resolution mechanism not yet defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Proved that chemerin-derived C-terminal peptides exert anti-inflammatory effects strictly through ChemR23, establishing the receptor as essential rather than redundant for resolution.\",\n      \"evidence\": \"In vivo zymosan peritonitis comparing wild-type and ChemR23-/- mice with neutralizing antibodies\",\n      \"pmids\": [\"18391062\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell type mediating anti-inflammatory effect not resolved\", \"Signaling pathway downstream not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined chemerin processing requirements and ChemR23-dependent chemotaxis/calcium responses across pDC, mDC, macrophage and NK populations, generalizing the receptor's chemoattractant role across innate immune cells.\",\n      \"evidence\": \"Flow cytometry, calcium and chemotaxis assays in ChemR23 KO mice plus pharmacological analysis of prochemerin processing\",\n      \"pmids\": [\"19841182\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of processing proteases not addressed\", \"G protein subtype usage not specified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extended CMKLR1 signaling to endothelium, linking inflammatory-cytokine-induced receptor upregulation to angiogenesis via PI3K/Akt and MAPK.\",\n      \"evidence\": \"Angiogenesis assays, gelatin zymography, and Western blot for PI3K/Akt and MAPK in human endothelial cells\",\n      \"pmids\": [\"20044979\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic KO confirmation\", \"Single lab\", \"G protein coupling not tested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Placed CMKLR1 in a PPAR\\u03b3-driven autocrine chemerin loop controlling the adipocyte-versus-osteoblast fate decision of stromal progenitors.\",\n      \"evidence\": \"siRNA knockdown, differentiation assays, and PPAR\\u03b3 overexpression rescue in primary bone marrow stromal cells\",\n      \"pmids\": [\"19929432\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream signaling controlling fate not defined\", \"In vivo relevance not tested in this study\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established CMKLR1 as a driver of macrophage phagocytosis and efferocytosis through Syk-dependent actin remodeling, defining a clearance function for the receptor.\",\n      \"evidence\": \"Phagocytosis/efferocytosis assays in ChemR23 KO macrophages with Syk inhibition, F-actin imaging, and in vivo peritoneal clearance\",\n      \"pmids\": [\"20363975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Link between G protein signaling and Syk activation not resolved\", \"Receptor-Syk physical coupling not shown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Showed chemerin-CMKLR1 drives a pro-inflammatory, catabolic program in chondrocytes via ERK and Akt, extending the receptor's signaling to cartilage pathology.\",\n      \"evidence\": \"Phospho-MAPK/Akt Western blots and cytokine/MMP measurement in primary human chondrocytes\",\n      \"pmids\": [\"21192818\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic KO confirmation\", \"Single lab\", \"G protein dependence not established\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Dissected opposing pro- and anti-inflammatory roles of ChemR23 in viral pneumonia, revealing leukocytic versus non-leukocytic compartments mediate distinct outcomes.\",\n      \"evidence\": \"ChemR23 KO mice, pneumovirus infection, pDC depletion, adoptive transfer, and chimeric mice\",\n      \"pmids\": [\"22072972\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular nature of the non-leukocytic anti-inflammatory pathway undefined\", \"Ligand driving each arm not separated\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established CMKLR1 as an in vivo regulator of adiposity, adipose immune composition, and glucose homeostasis, broadening its role from immunity into metabolism.\",\n      \"evidence\": \"CMKLR1 KO mouse body-composition, glucose tolerance/insulin secretion, immune flow cytometry, and tissue glucose uptake\",\n      \"pmids\": [\"22186410\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-autonomous versus systemic contributions not separated\", \"Signaling pathway mediating metabolic effects not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed CMKLR1 oligomerizes with CXCR4 and CCR7 with negative binding cooperativity, revealing cross-regulation of chemokine receptor systems at the membrane.\",\n      \"evidence\": \"BRET, HTRF, and radioligand competition assays validated in ChemR23 KO primary bone-marrow DCs\",\n      \"pmids\": [\"23469143\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of heteromerization in vivo not established\", \"Single lab\", \"Stoichiometry not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Defined a neutrophil-intrinsic C15/ChemR23 pathway that suppresses integrin activation and adhesion, providing a resolution mechanism protective in myocardial infarction.\",\n      \"evidence\": \"Granule localization imaging, integrin assays, intravital microscopy, and a murine MI model with ChemR23-dependent pharmacology\",\n      \"pmids\": [\"23999103\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Intracellular signaling linking receptor to integrin inactivation not mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Comprehensively defined CMKLR1 transduction: G\\u03b1i/o coupling, \\u03b2-arrestin1/2 recruitment, and the dual G\\u03b1i/o + \\u03b2-arrestin2 requirement for ERK, while distinguishing it from GPR1 and CCRL2.\",\n      \"evidence\": \"BRET biosensors for multiple G protein subtypes and \\u03b2-arrestins, radioligand binding, and ERK phosphorylation with pathway inhibitors\",\n      \"pmids\": [\"27716822\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of biased signaling not addressed\", \"Receptor desensitization kinetics not in scope\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified amyloid-\\u03b242 as a CMKLR1 ligand driving microglial migration and receptor internalization, linking the receptor to neuroinflammatory contexts.\",\n      \"evidence\": \"Binding in CMKLR1-transfected RBL cells, migration assays in microglia, pathway inhibitor studies, and internalization assays\",\n      \"pmids\": [\"25079809\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Physiological relevance in brain not tested in vivo\", \"Competition with chemerin not addressed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Mapped chemerin-CMKLR1 chemotaxis to a RhoA/ROCK/SRF and p38/G\\u03b1i/o axis, defining the cytoskeletal transcriptional output of the receptor.\",\n      \"evidence\": \"SRF/CRE/NF-\\u03baB luciferase reporters and pathway inhibitors with chemotaxis assays in L1.2 and AGS cells\",\n      \"pmids\": [\"26363224\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic KO confirmation\", \"Single lab\", \"Species-specific differences not fully resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Revealed promoter-driven differential ChemR23 expression across M1/M2 macrophages and RvE1-driven resolution-type repolarization, connecting receptor regulation to macrophage programming.\",\n      \"evidence\": \"5' RACE promoter identification, flow cytometry, qPCR, chemotaxis, and phagocytosis in primary human macrophages\",\n      \"pmids\": [\"25637017\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factors driving P3 usage not fully identified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated Gi-biased agonism at CMKLR1 mediating vasoconstriction and blood-pressure regulation, distinguishing its vascular pharmacology from GPR1.\",\n      \"evidence\": \"Vascular isometric tension, rat blood pressure, cAMP assays with selective antagonist CCX832, and immunohistochemistry\",\n      \"pmids\": [\"27742615\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Smooth-muscle contraction signaling downstream of Gi not fully mapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined the chemerin/chemerin-9 binding epitope on ChemR23 using conformation-specific nanobody antagonists, providing tools and a structural footprint of the ligand site.\",\n      \"evidence\": \"Nanobody development, competition binding, calcium and chemotaxis assays in primary cells\",\n      \"pmids\": [\"26864035\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution structure not determined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established that RvE1/ChemR23 restrains atherosclerosis by promoting macrophage clearance and limiting oxLDL uptake, defining an atheroprotective resolution axis.\",\n      \"evidence\": \"ChemR23/Apoe double KO mice, plaque histology, phagocytosis and oxLDL uptake assays, and plasma lipidomics\",\n      \"pmids\": [\"29739755\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Macrophage signaling linking receptor to oxLDL handling not fully resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed GRK6 phosphorylation and \\u03b2-arrestin2 control CMKLR1 internalization and tune macrophage migration and AKT/ERK output, defining receptor desensitization machinery.\",\n      \"evidence\": \"BRET/co-IP arrestin recruitment, internalization flow cytometry, and GRK6 KO/\\u03b2-arrestin2 KO primary macrophages with signaling Westerns\",\n      \"pmids\": [\"30576947\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific phosphorylation sites not mapped\", \"Other GRK contributions not excluded\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified a CMKLR1-PTEN-Akt axis through which chemerin suppresses hepatocellular carcinoma metastasis, revealing a tumor-suppressive receptor function.\",\n      \"evidence\": \"Co-IP of PTEN-CMKLR1, PTEN phosphatase/ubiquitination assays, and in vivo mouse metastasis models\",\n      \"pmids\": [\"29717200\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of PTEN-receptor interaction control not fully resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked chemerin-ChemR23 to keratinocyte inflammation via a ROS-sirt1-NF-\\u03baB pathway, connecting the receptor to psoriasis-like skin pathology.\",\n      \"evidence\": \"Cytokine ELISA, NF-\\u03baB/sirt1 Westerns, ROS measurement, and an imiquimod psoriasis model\",\n      \"pmids\": [\"30426542\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic KO confirmation\", \"Single lab\", \"G protein dependence not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified CMKLR1 as a determinant of VSMC osteoblastic phenotype switching and phosphate-induced calcification, with RvE1 acting protectively through the receptor.\",\n      \"evidence\": \"ChemR23 KO mice and primary VSMCs, calcification assays, phenotype markers, vitamin D3 model, and Fat-1 transgene\",\n      \"pmids\": [\"30597013\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Opposing chemerin versus RvE1 effects on calcification not reconciled mechanistically\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed chemerin via ChemR23 inhibits VSMC calcification by inducing matrix gla protein, indicating context-dependent receptor effects on vascular mineralization.\",\n      \"evidence\": \"Primary VSMC calcification assays in ChemR23 KO cells with MGP expression measurement\",\n      \"pmids\": [\"31197872\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic depth limited\", \"Single lab\", \"Reconciliation with osteoblastic-phenotype findings unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established a required chemerin-CMKLR1 axis for NK cell recruitment to tumors, mediating the antitumor effects of all-trans retinoic acid.\",\n      \"evidence\": \"Chemerin KO and CMKLR1 KO melanoma tumor models with flow cytometry of tumor-infiltrating NK cells and atRA treatment\",\n      \"pmids\": [\"31063220\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular source of chemerin in tumors not pinpointed\", \"Direct NK chemotaxis versus indirect effects not fully separated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined hematopoietic ChemR23 as proatherogenic by restraining M2 polarization and cholesterol efflux and promoting pDC lesion accumulation, demonstrating cell-autonomous immune function.\",\n      \"evidence\": \"Hematopoietic-specific KO via bone marrow transplant, pDC adoptive transfer, histology, and flow cytometry in Apoe-/- mice\",\n      \"pmids\": [\"30786742\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand (chemerin versus RvE1) driving this arm not separated\", \"Reconciliation with protective RvE1/ChemR23 atherosclerosis role unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed NLRP3 inflammasome activation downstream of chemerin-CMKLR1, linking the receptor to pyroptosis in diabetic cardiomyopathy.\",\n      \"evidence\": \"siRNA knockdown of CMKLR1 and NLRP3 in vivo and in vitro with epistasis, Western blots, and cell-death assays\",\n      \"pmids\": [\"32390873\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Knockdown only, no genetic KO\", \"Single lab\", \"Direct signaling link from receptor to NLRP3 not mapped\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extended the CMKLR1/PTEN axis to tumor immune evasion by showing chemerin suppresses PD-L1 via CMKLR1/PTEN/PI3K-AKT-mTOR signaling in prostate and sarcoma cells.\",\n      \"evidence\": \"CMKLR1 siRNA, pathway inhibitors, and forced-chemerin xenografts\",\n      \"pmids\": [\"32605911\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Knockdown rather than KO\", \"Direct receptor-PTEN coupling not re-demonstrated here\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated that ChemR23 is required for n-3 PUFA/RvE1-mediated protection against aortic valve stenosis, generalizing the resolution axis to valvular calcification.\",\n      \"evidence\": \"ChemR23 KO and Fat-1tg \\u00d7 Apoe-/- mice with echocardiography, histology, and lipidomics\",\n      \"pmids\": [\"32506925\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell type mediating valvular protection not pinpointed\", \"Downstream signaling not dissected\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed that agonist antibody engagement of ChemR23 is sufficient to drive efferocytosis and resolve chronic inflammation, validating the receptor as a therapeutic target.\",\n      \"evidence\": \"Agonist mAb characterization, efferocytosis and neutrophil-apoptosis assays, chronic colitis models, and IBD patient transcriptomics\",\n      \"pmids\": [\"33811066\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor signaling triggered by the agonist mAb not fully mapped\", \"Comparison to natural-ligand bias not addressed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified an adipocyte-autonomous CMKLR1 brake on cold-induced thermogenesis acting via cAMP-PKA-IL-33, linking the receptor to beige fat and type-2 immunity.\",\n      \"evidence\": \"Adipocyte-specific CMKLR1 KO mice, cold exposure, cAMP/PKA assays, IL-33 measurement, and metabolic phenotyping\",\n      \"pmids\": [\"34330814\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Gi-coupled CMKLR1 dampens cAMP in adipocytes mechanistically detailed but ligand source in adipose not specified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed an intestinal-epithelial CMKLR1-lactoperoxidase pathway restricting microbiota-driven neutrophilia and tumorigenesis, defining a non-hematopoietic protective function.\",\n      \"evidence\": \"IEC-specific CMKLR1 KO mice, microbiome and LPO analysis, neutrophil quantification, and LPO supplementation rescue\",\n      \"pmids\": [\"35858331\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling linking receptor to LPO induction not mapped\", \"Ligand driving epithelial CMKLR1 not identified\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed chemerin stabilizes CMKLR1 against proteasomal degradation to amplify NF-\\u03baB-driven glioblastoma mesenchymal transition and M2 TAM polarization.\",\n      \"evidence\": \"Co-IP, ubiquitination assays, NF-\\u03baB reporter, expression manipulation, GBM xenografts, and macrophage polarization assays with \\u03b1-NETA\",\n      \"pmids\": [\"35459783\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Ubiquitin ligase regulating CMKLR1 not identified\", \"Reconciliation with tumor-suppressive CMKLR1 roles unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined an RvE1/ChemR23 AMPK\\u03b1/Nrf2/NF-\\u03baB pathway in VSMCs that ameliorates hypertension and vascular remodeling, adding a metabolic-stress signaling output.\",\n      \"evidence\": \"AAV9 ChemR23 knockdown, Ang II hypertension model, signaling Westerns, blood pressure, and histology\",\n      \"pmids\": [\"37800344\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Knockdown rather than KO\", \"Single lab\", \"Direct receptor coupling to AMPK\\u03b1 not shown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established CMKLR1 as a controller of lipid uptake and storage in clear-cell renal carcinoma through ATGL, SREBP1c, and CD36 regulation, with pharmacological inhibition triggering tumor cell death.\",\n      \"evidence\": \"Genetic and pharmacological (\\u03b1-NETA) suppression, lipidomics/transcriptomics, PDX models, and ATGL/SREBP1c/CD36 Westerns\",\n      \"pmids\": [\"38640229\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling chain linking the GPCR to SREBP1c/CD36 not fully mapped\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How a single Gi/o-coupled receptor produces opposing outcomes\\u2014pro- versus anti-inflammatory, pro- versus anti-tumor, and pro- versus anti-calcific\\u2014depending on ligand (chemerin, RvE1, A\\u03b242), cell type, and signaling bias remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure of CMKLR1 with distinct ligands\", \"Ligand-specific biased signaling not mechanistically linked to divergent phenotypes\", \"Endogenous source and processing of chemerin in each tissue context not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [4, 16, 17]},\n      {\"term_id\": \"GO:0001618\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0004930\", \"supporting_discovery_ids\": [16, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [16, 20, 14]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [16, 18, 20]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [5, 9, 11, 19, 27]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [12, 34, 38]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"RARRES2\", \"CXCR4\", \"CCR7\", \"ARRB2\", \"GRK6\", \"PTEN\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}